

90

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86110125.1

(22) Date of filing: 23.07.86

(51) Int. Cl.⁴: C 07 K 5/00
 C 08 K 7/00, C 07 C 103/50
 C 07 D 233/64, A 61 K 37/64
 A 61 K 31/195, C 07 F 9/65
 A 61 K 31/66

(30) Priority: 24.07.85 US 758625

(43) Date of publication of application:
 28.01.87 Bulletin 87/5

(64) Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: MERCK & CO. INC.
 126, East Lincoln Avenue P.O. Box 2000
 Rahway New Jersey 07065(US)

(72) Inventor: Boger, Joshua S.
 719 New Gulph Road
 Bryn Mawr Pennsylvania 19010(US)

(72) Inventor: Bock, Mark G.
 1603 Leon Drive
 Hatfield Pennsylvania 19440(US)

(72) Inventor: Freidinger, Roger
 2185 Rebecca Drive
 Hatfield Pennsylvania 19440(US)

(72) Inventor: Veber, Daniel F.
 290 Batleson Road
 Ambler Pennsylvania 19002(US)

(72) Inventor: Patchett, Arthur A.
 1090 Minisink Way
 Westfield New Jersey 07090(US)


(72) Inventor: Greenlee, William J.
 115 Herrick Avenue
 Teaneck New Jersey 07666(US)

(72) Inventor: Persons, William H.
 2171 Oliver Street
 Rahway New Jersey 07065(US)

(74) Representative: Abitz, Walter, Dr.-Ing. et al,
 Abitz, Morf, Gritschneider, Freiherr von Wittgenstein
 Postfach 86 01 69
 D-8000 München 86(DE)

(54) Peptide enzyme inhibitors.

(57) Enzyme peptides of the formula



and analogs thereof which inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.

Renin is a proteolytic enzyme of molecular weight about 40,000, produced and secreted by the juxtaglomerular cells of the kidney. Renin acts on the plasma substrate, angiotensinogen, to split off the decapeptide angiotensin I, which is converted to the potent pressor agent angiotensin II. Thus, the renin-angiotensin system plays an important role in normal cardiovascular homeostasis and in some forms of hypertension.

In the past, attempts to modulate or manipulate the renin-angiotensin system have met with success in the use of inhibitors of angiotensin I converting enzyme. In view of this success, it was concluded that a specific inhibitor of the limiting enzymatic step that ultimately regulates angiotensin II production, the action of renin on its substrate, would be at least equally successful. Thus, an effective inhibitor of renin has been long sought as both a therapeutic agent and as an investigative tool.

20

2. Brief Description of the Prior Art

There has been substantial interest in the synthesis of useful renin inhibitors for many decades; and the following table lists the major classes of renin inhibitors that have been studied, as well as their relative inhibition constants (K_i):

Class	K_i (M)
Renin antibody	probably 10^{-6}
Pepstatin	$10^{-6} - 10^{-7}$
Phospholipids	10^{-3}
Substrat analogs	10^{-3}
Tetrapeptides	$10^{-5} - 10^{-6}$
Octa- to tridecapeptides	$10^{-5} - 10^{-6}$

41180/1213A

- 4 -

170081B

renin substrate, human renin, on the other hand, does cleave the pig renin substrate. See Poulsen et al., Biochim. Biophys. Acta 452:533-537, 1976; and Skeggs, Jr. et al., J. Exp. Med. 106:439-453, 1957. Moreover, the human renin inhibitory activity of the peptides of the present invention most active in inhibiting pig renin has been confirmed, thus providing further evidence of this accepted correlation between human and pig renin activity.

It has been found, for example, using pig renin substrate analogy, that the octapeptide sequence extending from histidine-6 through tyrosine-13 has kinetic parameters essentially the same as those of the full tetradecapeptide renin substrate. The amino acid sequence of the octapeptide in pig renin substrate is as follows:

6 7 8 9 10 11 12 13
-His-Pro-Phe-His-Leu-Leu-Val-Tyr-

Renin cleaves this substrate between Leu¹⁰ and Leu¹¹.

Kokubu et al., Biochem. Pharmacol. 22: 3217-3223, 1973, synthesized a number of analogs of the tetrapeptide found between residues 10 to 13, but while inhibition could be shown, inhibitory constants were only of the order of 10^{-3} M.

Analogues of a larger segment of renin substrate were also synthesized: Burton et al., Biochemistry 14: 3892-3898, 1975, and Poulsen et al., Biochemistry 12: 3877-3882, 1973. Two of the major obstacles which had to be overcome to obtain an effective renin inhibitor useful in vivo were lack of

state for pepsin hydrolysis of peptide bonds.
However, the applicability of these concepts to renin
inhibitors is not taught in any of these references,
and would be speculative due to the known high degree
5 of specificity of the renin enzyme.

Kokubu et al., Biochem. Biophys. Res. Comm.
118:929-933, 1984; and Fehrentz et al., FEBS Letters
167: 273-276, 1984, have prepared a renin inhibitor
in which a C-terminal aldehyde is used to mimic
10 Leu¹⁰ of the substrate. However, there is no
suggestion of the renin inhibitors of the present
invention in which statine and other moieties replace
Leu¹⁰-Leu¹¹ of the substrate.

Veber and Rich, in U.S. Patent No. 4,384,994
15 and published European Patent Application No.
0,077,029; Evans and Rittle, in U.S. Patent No.
4,397,786; Veber and Boger, in published European
Patent Application No. 0,077,028; Boger et al., Nature,
303:81-84 (1983); have all described renin inhibitory
20 peptides containing statine; and in Nature there is
further described renin inhibitors having a shortened
C-terminus, with a non-peptide ending after the
11-position. However, none of these references
describe or suggest the renin inhibitors of the
25 present invention and the significant increase in
renin inhibitory activity obtainable therewith.
Moreover, the Nature reference teaches away from renin
inhibitors having non-peptide components after the
11-position, as with the inhibitors of the present
30 invention.

For other articles describing previous
efforts to devise renin inhibitors, see Marshall,
Federation Proc. 35: 2494-2501, 1976; Burton et al.,

5

$$\begin{array}{c} R^1 \\ | \\ CH_2 \\ | \\ \begin{array}{cc} -N & C- \\ | & || \\ H & O \end{array} \end{array}$$

15 D is


20

$$\begin{array}{c} \text{R}^5 \\ | \\ (\text{CH}_2)_m \\ | \\ \text{---N} \quad \text{C---} \\ | \quad \parallel \\ \text{H} \quad \text{O} \end{array}$$

25

G is (1)

where q is 1 to 4;
X is O, or H, H;




41180/1213A

- 10 -

170081B

wherein X' is hydroxy; OR_4' wherein R_4' is as defined below; amino; or mono- or di- C_{1-4} alkyl amino; and W' is absent; $-O-$; $-NH-$; or $-CH_2-$;

5



10

where X'' and X''' are independently

absent; or $\overset{O}{\underset{\uparrow}{S}}$; and

15

W'' is absent; $-CH_2-$; or $-CH-$,
where R^8 is hydrogen or C_{1-3} alkyl;

20




25




; where R is hydrogen; C_{1-4} alkyl; formyl; C_{1-4} alkanoyl; aroyl; carboxy; C_{1-4} alkoxy carbonyl; aryl-oxycarbonyl; or aryl C_{1-4} alkoxy carbonyl; or

30

(2)



heterocyclic C₁₋₄alkyl;
 N(R')⁺₃A⁻, where R' is as
 defined above, and A⁻ is a counterion;
 guanidyl; heterocyclic; heterocyclic
 substituted with up to five members
 independently selected from the group
 consisting of C₁₋₆alkyl, hydroxy,
 trifluoromethyl, C₁₋₄alkoxy, halo,
 aryl, aryl C₁₋₄alkyl, amino, and
 mono- or di-C₁₋₄alkylamino; or
 heterocyclic substituted with another,
 the same or different, heterocyclic;



where

Y is as defined above;

n_a is 0 or 1;

n_b is 1 to 4;

n_c is 0 or 1;

n_d is 0 or 1;

n_e is 0 or 1, provided that n_e
 cannot be 1 when n_d is 0;

n_f is 1 to 4;

R⁴ is hydrogen; or $\text{---}\underset{\underset{\text{R}^3}{\text{C}}}{\text{CH}}\text{---R}^9$, where


R⁹ is hydrogen; C₁₋₄alkyl;
 hydroxy; or

C₃₋₇cycloalkyl; and R³ is
 hydrogen; C₁₋₄alkyl; aryl;

41180/1213A

- 14 -



170081B



where

n is 0 or 1; or

5



10

where

Y is -NH- or -O-;

q is 1-5;

q' is 0-5;

15

 R^{10} is hydrogen; hydroxy; $\text{N}(\text{R}^*)_2$,where R^* may be the same or different and is hydrogen or C_{1-4} alkyl; guanidyl; or $\text{N}^{\oplus}(\text{R}^*)_3\text{A}^{\ominus}$, where R^* is as defined above, and A^{\ominus} is a

20

counterion; provided that at least one R^{10} is not hydrogen;
 R^{11} is C_{1-4} alkyl; C_{3-7} cycloalkyl; aryl; aryl substituted with up to three members independently selected from the group consisting of

25

 C_{1-6} alkyl, trifluoromethyl, hydroxy, C_{1-4} alkoxy, amino, mono- or di- C_{1-4} alkylamino, amino


30

 C_{1-4} alkyl, mono-, di-, or tri- C_{1-4} alkylamino- C_{1-4} alkyl, halo, carboxy, carboxy ester or amide, carboxy- C_{1-4} -alkoxy, carboxy- C_{1-4} -alkoxy ester or amide, α -aminocarboxy-

41180/1213A


- 16 -

17008IB



5

or



10

where

Y is -NH- or -O-;

k is 0-4;

k' is 0 or 1;


k'' is 0-4;

15

k''' is 0 or 1;

R' is hydrogen or C₁₋₄ alkyl; andR'' is hydrogen or C₁₋₄ alkyl;

20



25

where Z is NH, N-R⁷, O, S or CHR⁷;

n' is 0 to 5; and

R^{7a} is hydrogen, hydroxy,C₁₋₄-alkyl, C₃₋₇-cydoalkyl, aryl, aryl substituted with from one to five members independently selected from the group

30

consisting of C₁₋₆-alkyltrifluoromethyl, hydroxy, C₁₋₄ alkoxy,amino, mono- or di- C₁₋₄ alkylamino,and halo; N(R')₂, where R' may be the same or different and is hydrogen,

41180/1213A

- 18 -

170081B

included in the peptides of the present invention, preferred chiralities are indicated in the description which follows.

5 In the above definitions, the term "alkyl" is intended to include both branched and straight chain hydrocarbon groups having the indicated number of carbon atoms.

The term "halo" means fluoro, chloro, bromo and iodo.

10 The aryl substituent represents phenyl, and naphthyl.

The heterocyclic substituent recited above represents any 5- or 6-membered ring containing from one to three heteroatoms selected from the group
15 consisting of nitrogen, oxygen, and sulfur; having various degrees of unsaturation; wherein the nitrogen and sulfur heteroatoms may optionally be oxidized; wherein the nitrogen heteroatom may optionally be quaternized; and including any bicyclic group in which
20 any of the above heterocyclic rings is fused to a benzene ring. Heterocyclic substituents in which nitrogen is the heteroatom are preferred, and of these, those containing a single nitrogen atom are preferred. Fully saturated heterocyclic substituents are also
25 preferred. Thus, piperidine is a preferred heterocyclic substituent. Other preferred heterocyclic substituents are: pyrrol, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl,
30 piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl,

41180/1213A

- 20 -


170081B

It will be understood that closely related
 analogs of the above common amino acids, for example,
 aliphatic amino acids in addition to Ala, Val, Leu,
 and Ile, such as α -aminobutyric acid (Abu), and
 5 substituted phenyl derivatives of Phe, are included in
 the broad description of the novel inhibitory peptides
 of the present invention represented by Formula I and
 its definitions. Thus, the peptides of Formula II and
 its definitions represent preferred peptides of the
 10 present invention.


Preferred inhibitory peptides of the present
 invention are the following:

BOC¹-His-Pro-Phe-His-Sta-OEt

15



25



30


BOC-Phe-His-ACHPA²-NH₂
 BOC-HomoPhe-His-Sta-NH₂

0209897


4118o/1213A

- 22 -


170081B




5




10



15



20



25

30


0209897

4118o/1213A


- 24 -

17008IB


5



10




15



20

25




30

0209897

41180/1213A

- 26 -

170081B







0209897

4118o/1213A

- 28 -

17008IB







0209897

41180/1213A

- 30 -

170081B







0209897

41180/1213A

- 32 -

17008IB







0209897

4118o/1213A

- 34 -

170081B







0209897

41180/1213A

- 36 -

170081B







0209897

41180/1213A

- 38 -

170081B







0209897

41180/1213A

- 40 -

170081B







0209897

41180/1213A

- 42 -





170081B



4118o/1213A

- 44 -





170081B



41180/1213A

- 46 -

170081B







0209897

41180/1213A

- 48 -

170081B



0209897

41180/1213A

- 50 -

170081B

5

BOC-Phe-His-ACHPA



10

BOC-Phe-His-ACHPA




15

BOC-Phe-His-ACHPA



20

BOC-Phe-His-ACHPA




25

BOC-Phe-His-ACHPA



30

BOC-Phe-His-ACHPA




0209897


41180/1213A

- 52 -


17008IB




5




10



15




20



25



30




0209897

41180/1213A


- 54 -

17008IB


5




10




15




20



25



30




41180/1213A


- 56 -

170081B


5




10




15




20









25







30



17008IB






41180/1213A


- 62 -

170081B


5




10




15



20



25

30 BOC-Phe-His-ACHPA-C₆H₁₂O₅NBOC-Phe-His-ACHPA-C₅H₁₀O₄N

41180/1213A

- 64 -

170081B

- i-PRO₂C-His-His-ACHPA-NH-[(2S)-methyl]butyl
EtO₂C-Phe-His-ACHPA-NH-[(2S)-methyl]butyl
2(S)-hydroxy-3-phenylpropionyl-His-ACHPA-NH-[2S)-
methyl]butyl
5 S-benzylthioacetyl-His-ACHPA-NH-[(2S)-methyl]butyl
Dibenzylacetyl-His-ACHPA-NH-[(2S)-methyl]butyl
Bis-(naphthylmethyl)acetyl-His-ACHPA-NH-[(2S)-methyl]
butyl
Bis-(p-hydroxyphenylmethyl)acetyl-His-ACHPA-NH-[(2S)-
10 methyl]butyl
[2-Phenylamino-3-phenylpropionyl-His-ACHPA-NH-[(2S)-
methyl]butyl
2-Phenylloxy-3-phenylpropionyl]-His-ACHPA-NH-[(2S)-
methyl]butyl
15 2-Phenylthio-3-phenylpropionyl-His-ACHPA-NH-[(2S)-
methyl]butyl
1,3-Diphenylpropyloxcarbonyl-His-ACHPA-NH-[(2S)-methyl-
butyl
2-(1,3-diphenyl)propyloxcarbonyl-His-ACHPA-NH-[(2S)-
20 methyl]butyl
2-Phenylthio-3-(1-naphthyl)propionyl-His-ACHPA-NH-[(2S)-
-methyl]butyl
[2-benzyl-2-(3,4-dihydroxy)benzyl]acetyl-His-ACHPA-NH-[
(2S-methyl]butyl
25 [2-benzyl-2-(4-isopropoxy)benzyl]acetyl-His-ACHPA-NH-
[(2S)-methyl]butyl
BOC-Phe-His-[5-amino-6-cyclohexyl-4-hydroxy-2-
isopropyl]hexanoyl 2(S)-aminobutane
BOC-Phe His-[5-amino-6-cyclohexyl-4-hydroxy-2-
30 isobutyl]hexanoyl 2(S)-aminobutane
BOC-Phe-His-[5-amino-2-benzyl-6-cyclohexyl-4-hydroxy]
hexanoyl 2(S)-aminobutane


41180/1213A

- 66 -

170081B

Pro	Phe	His	Leu	Leu	Val	Tyr	
7	8	9	10	(11)	12	13	(14)

5



10

As can be seen, a unique aspect and essential feature of the present invention is the substitution of the G component for the double amino acid sequence: Leu¹⁰-Leu¹¹ in the endogenous pig renin substrate. It is believed that substitution of this component for both leucine amino acids rather than just one leucine results in an improved substrate analogy due to the greater linear extent of the component as compared to a single leucine component. Thus, the component more closely approximates Leu-Leu in linear extent, and thereby provides a better "fit" to the renin enzyme.

The inhibitory peptides of the present invention may also be better appreciated in terms of substrate analogy from the following illustration of Formula I alongside the octapeptide sequence of a portion of the human renin substrate, which renin cleaves between Leu¹⁰ and Val¹¹:

30	Pro	Phe	His	Leu	Val	Ile	His	
	7	8	9	10	(11)	12	13	(14)

cyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with
5 organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl,
10 ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and
15 phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

The present invention is also directed to combinations of the novel renin-inhibitory peptides of Formula I with one or more antihypertensive agents
20 selected from the group consisting of diuretics, α and/or β -adrenergic blocking agents, CNS-acting agents, adrenergic neuron blocking agents, vasodilators, angiotensin I converting enzyme inhibitors, calcium channel blockers, and other
25 antihypertensive agents.

For example, the compounds of this invention can be given in combination with such compounds or salt or other derivative forms thereof as:

30 Diuretics: acetaz lamide; amil ride; bendroflumethiazide; benzthiazide; bumetanide; chlorothiazide; chlorthalidone; cyclothiazide; ethacrynic acid; furosemide; hydrochlorothiazide;

- (α -[(tert.butylamino)methyl]-7-ethyl-2-benzofuran-methanol) (bufuralol);
- (3-[3-acetyl-4-[3-(tert.butylamino)-2-hydroxypropyl]-phenyl]-1,1-diethylurea HCl) (celiprolol);
- 5 ((\pm)-2-[2-[3-[(1,1-dimethylethyl)amino]-2-hydroxy-propoxy]phenoxy]-N-methylacetamide HCl) (cetamolol);
- (2-benzimidazolyl-phenyl(2-isopropylaminopropanol));
- ((\pm)-3'-acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)-
- 10 acetanilide HCl) (diacetolol);
- (methyl-4-[2-hydroxy-3-[(1-methylethyl)aminopropoxy]]-benzenepropanoate HCl) (esmolol);
- (erythro-DL-1-(7-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol);
- 15 (1-(tert.butylamino)-3-[O-(2-propynyloxy)phenoxy]-2-propanol (pargolol);
- (1-(tert.butylamino)-3-[o-(6-hydrazino-3-pyridazinyl)-phenoxy]-2-propanol diHCl) (prizidilol);
- ((-)-2-hydroxy-5-[(R)-1-hydroxy-2-[(R)-(1-methyl-3-
- 20 phenylpropyl)amino]ethyl]benzamide);
- (4-hydroxy-9-[2-hydroxy-3-(isopropylamino)-propoxy]-7-methyl-5H-furo[3,2-g][1]-benzopyran-5-one) (iprocrolol);
- ((-)-5-(tert.butylamino)-2-hydroxypropoxy]-3,4-dihydro-
- 25 1-(2H)-naphthalenone HCl) (levobunolol);
- (4-(2-hydroxy-3-isopropylamino-propoxy)-1,2-benzisothiazole HCl);
- (4-[3-(tert.butylamino)-2-hydroxypropoxy]-N-methylisocarbostyryl HCl);
- 30 ((\pm)-N-2-[4-(2-hydroxy-3-isopropyl aminopropoxy)-phenyl]ethyl-N'-isopropylurea) (pafenolol);
- (3-[[2-(trifluoroacetamido)ethyl]amino]-1-phenoxypropan-2-ol);

41180/1213A

- 72 -

170081B

- ((1-tert.butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol) (nadolol);
- ((S)-1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)-amino]-2-propanol sulfate (2:1)) (penbutolol);
- 5 (4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide) (sotalol);
- (2-methyl-3-[4-(2-hydroxy-3-tert.butylaminopropoxy)-phenyl]-7-methoxy-isoquinolin-1-(2H)-one);
- (1-(4-(2-(4-fluorophenoxy)ethoxy)phenoxy)-3-iso-propylamino-2-propanol HCl);
- 10 ((-)-p-[3-[(3,4-dimethoxyphenethyl)amino]-2-hydroxypropoxy]-β-methylcinnamionitrile) (pacrinolol);
- ((±)-2-(3'-tert.butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole HCl)
- 15 (arotinolol);
- ((±)-1-[p-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(isopropylamino)-2-propanol) (cicloprolol);
- ((±)-1-[(3-chloro-2-methylindol-4-yl)oxy]-3-[(2-phenoxyethyl)amino]-2-propanol) (indopanolol);
- 20 ((±)-6-[[2-[[3-(p-butoxyphenoxy)-2-hydroxypropyl]-amino]ethyl]amino]-1,3-dimethyluracil) (pirepolol);
- (4-(cyclohexylamino)-1-(1-naphtholenyloxy)-2-butanol);
- (1-phenyl-3-[2-[3-(2-cyanophenoxy)-2-hydroxypropyl]-aminoethyl]hydantoin HCl);
- 25 (3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran) (nipradolol);

α and β-Adrenergic Blocking Agents:

- 30 ((±)-1-tert-butylamino)-3-[o-[2-(3-methyl-5-isoxazolyl)vinyl]phenoxy]-2-propanol) (isoxaprolol);
- (1-isopropylamino-3-(4-(2-nitroxyethoxy)phenoxy)-2-propanol HCl);

41180/1213A

- 74 -

170081B

- ((S)-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid HCl);
- (N-cyclopentyl-N-(3-(2,2-dimethyl-1-oxopropyl)thiol-2-methyl-1-oxopropyl)glycine) (pivalopril);
- 5 ((2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid);
- (1-(N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl)-cis,syn-octahydroindol-2(S)-carboxylic acid HCl);
- 10 ((-)-(S)-1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-indoline-2-carboxylic acid);
- ([1(S),4S]-1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-phenylthio-L-proline;
- (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1-acetic acid HCl);
- 15 (N-(2-benzyl-3-mercaptopropanoyl)-S-ethyl-L-cysteine) and the S-methyl analogue;
- (N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline maleate) (enalapril);
- 20 N-[1-(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline;
- N²-[1-(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lysinoapril);
- 25 Calcium Channel Blockers:
- α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-propyl]-3,4-dimethoxy- α -(1-methylethyl)benzene-acetonitrile (verapamil);
- 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
- 30 (nifedipine);
- 2-(2,2-dicyclohexylethyl)piperidine (perhexiline);
- N-(1-methyl-2-phenylethyl)-phenylbenzenepropanamine (prenylamine);

41180/1213A

- 76 -

17008IB

Other Antihypertensive Agents: aminophylline; cryptenamine acetates and tannates; deserpidine; meremethoxylline procaine; pargyline; trimethaphan camsylate;

5 and the like, as well as admixtures and combinations thereof.

Typically, the individual daily dosages for these combinations can range from about one-fifth of the minimally recommended clinical dosages to the
10 maximum recommended levels for the entities when they are given singly. Coadministration is most readily accomplished by combining the active ingredients into a suitable unit dosage form containing the proper dosages of each. Other methods of coadministration
15 are, of course, possible.

The novel peptides of the present invention possess an excellent degree of activity in treating renin-associated hypertension and hyperaldosteronism. Some of the peptides also have ACE inhibitor activity
20 which may also make them useful for treating hypertension and congestive heart failure.

For these purposes the compounds of the present invention may be administered parenterally, by inhalation spray, or rectally in dosage unit formu-
25 lations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In
30 addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.

41180/1213A

- 78 -


170081B

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

5 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of
10 administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

Thus, in accordance with the present invention there is further provided a pharmaceutical
15 composition for treating renin-associated hypertension and hyperaldosteronism, or congestive heart failure comprising a pharmaceutical carrier and a therapeutically effective amount of a peptide of the formula:

20



25

wherein A, B, D, E, R^1 , G, and J have the same meaning as recited further above for Formula I; wherein all of the asymmetric carbon atoms have an S
30 configuration, except for those in the B, D, and G substituents, which may have an S or R configuration; and a pharmaceutically acceptable salt thereof.

41180/1213A

- 80 -

170081B

hypotensive dosage level and as a single dose, and there may result a transitory fall in blood pressure. This fall in blood pressure, if it occurs, indicates supranormal plasma renin levels.

5 An in vitro method which may be employed involves incubating a body fluid, preferably plasma, with a novel peptide of the present invention and, after deproteinization, measuring the amount of angiotensin II produced in nephrectomized, pento-
10 linium-treated rats. Another in vitro method involves mixing the plasma or other body fluid with a novel peptide of the present invention and injecting the mixture into a test animal. The difference in pressor response with and without added peptide is a
15 measure of the renin content of the plasma.

 Pepstatin may be employed in the methods described above as an active control. See, e.g., U.S. Patent Nos. 3,784,686 and 3,873,681 for a description of the use of pepstatin in diagnostic
20 methods of this type.

 The novel peptides of the present invention may be prepared in accordance with well-known procedures for preparing peptides from their constituent amino acids, which will be described in
25 more detail below.

 A general method of preparation may be described in the following terms:

 A method of preparing a peptide of Formula I, said peptide being comprised of from two to six
30 amino acids identified as I through VI, amino acid (AA) I being the component G at the C-terminus of said peptide, and amino acid (AA) VI being at the

(G) treating the ttipeptide through hexapeptide

said method also comprising, where necessary, protection of sidechain substituents of the component amino acids AA I through AA VI, with deprotection being


15 carried out as a final step; said method also
comprising any combination of the steps set out
above, whereby the amino acids I through VI and
substituents A, G, and J, are assembled in any
desired order to prepare the peptide of Formula I;
20 and said method also comprising employment of the
steps set out above in a solid phase sequential
synthesis, whereby in the initial step the carboxyl
group of the selected amino acid is bound to a
synthetic resin substrate while the amino group of
25 said amino acid is protected, followed by removal of
the protecting group, the succeeding steps being as
set out above, the peptide as it is assembled being
attached to said synthetic resin substrate; followed
by a step of removing the peptide of Formula I from
30 said synthetic resin substrate; and after removal of
the peptide of Formula I from said synthetic resin
substrate, the step of treating said ester thereof in
accordance with the procedures described in Step (C)

41180/1213A

- 84 -

17008IB


involve addition of the isostere component in a protected form. For example, the following reactive groups would require such protection:



Such protecting groups may be removed as a final or near final step, for example, by base hydrolysis in the former case, or by hydrogenation in the latter.

Preparation of the particular isostere components may be carried out in accordance with procedures described below and in the literature cited particularly as follows:


20



25

Ondetti et al., Chemistry and Biology of Peptides, ed. J. Meienhofer, Ann. Arbor Science pp. 525-531, 1972.


30



41180/1213A

- 86 -


170081B



5


- (1) Natarajan et al., Id.
- (2) Hann et al., J. Chem. Soc. Chem. Comm.,
234-235, 1980.
- (3) Cox et al., J. Chem. Soc. Chem. Comm.,
799-800, 1980.

10



15

Ondetti et al., Id.



20

- (1) Van Lommen et al., Id.
- (2) Atherton et al., J. Chem. Soc. (C),
3393-3396, 1971.
- (3) Parry et al., Chemistry and Biology of Peptides, ed. J. Meienhofer, Ann Arbor Science, pp. 541-544, 1972.
- (4) Hudson et al., Int. J. Peptide Protein Res.
15: 122-129, 1979.
- (5) Frank and Desiderio, Anal. Biochem. 90:
413-419, 1978.


25

30

41180/1213A

- 88 -

17008IB



30 (mixture of two pairs of diastereomers; two isomers at *; active isomer indicated).

which can be incorporated into the synthesis for the overall peptide of the present invention, or converted to the α -BOC derivative by hydrogenation over Pd/C catalyst, followed by treatment with

41180/1213A


- 90 -

170081B


(active isomer shown; other isomers obtained as well)

Incorporation of (IV.) or its N-BOC analog proceeds as for (III.) above, with removal of the methyl phosphinate ester by hydrolysis (alkaline) to give the free phosphinate. The active isomer shown at * has the side chains in the relative configuration of the dipeptide that they mimic. For synthesis of

10



15




20

Morton et al., Id.

For example, the compound:

25




30

can be prepared in accordance with the following scheme:

41180/1213A


- 92 -

170081B

The sulfone () can be obtained using excess *m*-Cl-perbenzoic acid.


5

Use of




second step gives as the final product:

10



15

K.




20

Prepared from the alcohol; see Rich *et al.*, Biochem. Biophys. Res. Comm. 104:1127-1133, 1982.

Conversion of the ketone to the thioketone is with use of:

25



30





L.



41180/1213A

- 94 -

17008IB




41180/1213A

- 96 -

170081B


M.




5

Obtained from the amide according to the method described by Clausen *et al.*, Seventh American Peptide Symposium, 1981:


10



80°C; 0.5 Hour




15



20

N.



25

30


- (1) Natarajan *et al.*, *Id.*
- (2) Fok and Yankellov, *Id.*
- (3) Spatola *et al.*, *Id.*
- (4) Spatola and Bettag, *Id.*
- (5) Spatola *et al.*, Proceedings of the Seventh American Peptide Symposium, ed. E. Gross and D. H. Rich, pp. 613-616, 1981.

41180/1213A

- 98 -

170081B

The configurations of the chiral centers can be established as follows: treatment of the phthalimido methyl esters **3a** and **3b** with excess hydrazine gives the respective amino acyl hydrazides **4a** and **4b**, which are then converted in a two step/one pot procedure to the corresponding lactams **5a** and **5b**, to which stereochemical assignments can be made based on PMR analysis. These reactions may be illustrated as follows:




Alternatively, the benzyl ester **6**, rather than the methyl ester, may be used to form the ketone silylacetal **7**, which can then be reacted with phthalyl phenylalanine aldehyde and phthalyl leucine

41180/1213A

- 100 -

17008IB



III. Where the Component G Is the Amino Acid
Statine Itself: it may be prepared in accordance with
 the procedure described by Rich et al., J. Org. Chem.
 43: 3624, 1978.

41190/1252A

- 102 -

17008IB

TABLE I

<u>Abbreviated Designation</u>		<u>Amino Acid</u>
	Ala	L-alanine
5	Arg	L-arginine
	Gly	L-glycine
	His	D or L-histidine
	Ile	L-isoleucine
	Leu	L-leucine
10	Lys	L-lysine
	Met	L-methionine
	Orn	L-ornithine
	Phe	L-phenylalanine
	Ser	L-serine
15	Sar	L-sarcosine
	(N-methylglycine)	
	Thr	L-threonine
	Trp	L-tryptophan
	Tyr	L-tyrosine
20	Val	L-valine
<u>Abbreviated Designation</u>		<u>Protecting Groups</u>
25	BOC	tert-butyloxycarbonyl
	CBZ	benzyloxycarbonyl
	DNP	dinitrophenyl
	OMe	methyl ester
<u>Abbreviated Designation</u>		<u>Activating Groups</u>
30	HBT	1-hydroxybenzotriazole

41190/1252A

- 104 -

17008IB

ether and stannic chloride. The Friedel-Crafts reaction is continued until the resin contains 0.5 to 5 mmoles of chlorine per gram of resin.

5 The amino acid selected to be the C-terminal amino acid of the linear peptide is converted to its amino protected derivative. The carboxyl group of the selected C-terminal amino acid is bound covalently to the insoluble polymeric resin support, as for example, as the carboxylic ester of the resin-bonded
10 benzyl chloride present in chloromethyl-substituted polystyrene-divinylbenzene resin. After the amino protecting group is removed, the amino protected derivative of the next amino acid in the sequence is added along with a coupling agent, such as dicyclo-
15 hexylcarbodiimide. The amino acid reactant may be employed in the form of a carboxyl-activated amino acid such as ONP ester, an amino acid azide, and the like. Deprotection and addition of successive amino acids is performed until the desired linear peptide
20 is formed.

The selection of protecting groups is, in part, dictated by particular coupling conditions, in part by the amino acid and peptide components involved in the reaction.


25 Amino-protecting groups ordinarily employed include those which are well known in the art, for example, urethane protecting substituents such as benzyloxy-carbonyl (carbobenzoxy), p-methoxycarbonyloxy, p-nitrocarbobenzoxy, t-butyloxycarbonyl, and
30 the like. It is preferred to utilize t-butyloxy-carbonyl (BOC) for protecting the α -amino group in the amino acids undergoing reaction at the carboxyl end of said amino acid. The BOC protecting group is

41190/1252A

- 106 -

17008IB


Step A.



To an ice cold, stirred solution of
10 BOC-statine ethyl ester 3 (2.60 g, 8.57 mmole) in
10 ml of pyridine is added via syringe 0.66 ml (8.57
mmole) of trifluoromethane sulfonyl chloride. Within
minutes, pyridinium hydrochloride precipitates from
solution. The reaction mixture is protected from
15 moisture and allowed to stand at room temperature
overnight. The reaction mixture is filtered and the
filtrate concentrated to give a light orange oil.
The crude product is filtered through 5-10 g of
silica gel (ether elution) to give 3.0 g of a pale
20 yellow oil which is used without further
purification. Compound 4 is prone to hydrolysis to 3
and must be used without delay.

Step B.

25



30

1,5-Diazabicyclo[4.3.0]non-5-ene (DBN)
(0.94 ml, 7.54 mmole) is added in one portion to a


41190/1252A

- 108 -

17008IB

The aqueous phase is acidified with 10% citric acid and extracted with ether and chloroform. The combined organic extracts are washed with brine and dried (Na_2SO_4). Concentration under reduced pressure affords 1.46 g of 6.

Step D.



15 The acid 6 (400 mg, 1.6 mmole) is dissolved in 4 ml of methylene chloride under nitrogen. N-methylmorpholine (0.18 ml, 1.6 mmole) is added and the solution is cooled to -5°C . Isobutylchloroformate (0.21 ml, 1.6 mmole) is added and after 15 minutes, 20 0.22 ml (1.92 mmole) of benzylamine is added to the reaction mixture. After 30 minutes at -5°C the reaction mixture is warmed to room temperature, stirred 1 hour more and diluted with 70 ml of methylene chloride. The organic phase is washed in 25 succession with 10% citric acid (2 x 30 ml), saturated sodium bicarbonate solution (2 x 30 ml), and brine. The organic extracts are dried (Na_2SO_4) and concentrated to yield 460 mg of a white solid identified as 7.


30

41190/1252A

- 110 -

17008IB

Step G.



15 The hydrazide 2 (240 mg, 0.42 mmole) is dissolved in 2 ml of dry dimethylformamide under nitrogen. The solution is cooled to -20°C and the pH of the reaction mixture adjusted to approximately 0.5-1.0 with tetrahydrofuran saturated with hydrogen

20 chloride. Isoamyl nitrite is then added in 50 µl increments at 15-20 minute intervals until a positive potassium iodide-starch test is obtained (250 µl total). The amine salt 8 (190 mg, 0.67 mmole) is dissolved in 2 ml of dimethylformamide and added to

25 the reaction mixture. After addition is complete, the pH of the reaction mixture is adjusted to 7.5-8.0 with triethylamine and the reaction mixture is allowed to stir at -20°C for 20 hours. The reaction is filtered and the filtrate concentrated. The


30 resulting residue is partitioned between ethyl acetate and water. The organic phase is washed in succession with 10% citric acid solution (2 x 50 ml), 50% sodium bicarb nate solution (2 x 50 ml), and

41190/1252A

- 112 -

170081B

Step B.



10 A rapidly stirred suspension of 3 (1.82 g, 3.95 mmole) in 15 ml of dry tetrahydrofuran is treated dropwise under nitrogen at 0°C with n-butyl lithium (1.4N, 2.82 ml, 3.95 mmole). The reaction mixture, which becomes homogeneous and colors to dark brown, is cooled to -78°C and treated with 5 ml of

15 tetrahydrofuran containing 0.5 g (2.32 mmole) of BOC-leucine aldehyde 1. After four hours at -78°C the reaction mixture is warmed to -10°C for 1 hour and then quenched with saturated ammonium chloride solution. The reaction is partitioned between ether

20 and brine. The organic phase is then washed with 10% citric acid solution (3 x 20 ml), 50% sodium bicarbonate solution (3 x 20 ml), and brine. Rotoevaporation of the dried (Na₂SO₄) extracts affords 0.42 g of crude product as a yellow oil. The

25 analytical sample is obtained by chromatography of the crude product on silica gel (hexane-ethyl acetate 9:1 elution).

41190/1252A


- 114 -

170081B

identical reaction conditions as described in Example 1, Step G]. The amine salt 5 (160 mg, 0.63 mmole) is then added [and the reaction is carried out and worked-up as described in Example 1, Step G].


- 5 The analytical sample (70 mg) is obtained after silica gel chromatography (80:10:1 CHCl_3 -ethanol-ammonia elution) as a pale yellow solid.

10

EXAMPLE 3

15

Step A.



- 30 N-Methylmorpholine (9.14 ml, 83.2 mmole), and BOC-leucine hydrate (20.0 g, 83.2 mmole) are dissolved in CH_2Cl_2 (200 ml) and the solution cooled to -5°C . Isobutylchloroformate (10.8 ml, 83.2 mmole) is added and the solution stirred 15 min. Benzylamine (10.9 ml, 99.8 mmol) is added and the solution stirred 15 min. The solution is warmed to

BOC-Phe-Phe-Sta-OH (240 mg, 0.421 mmole), diamine dihydrochloride **3** (130 mg, 0.466 mmole), 1-hydroxybenzotriazole hydrate (HBT) (62.9 mg, 0.466 mmole), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (895 mg, 0.466 mmole) are dissolved in degassed dimethylformamide (4 ml) under a nitrogen atmosphere. The pH of the

41190/1252A


- 118 -

170081B

mg, 0.2 mmole), 2-pyridylpiperazine 33.5 μ l, 35 mg, 0.22 mmole) diphenylphosphonylazide (47.5 μ l, 60.7 mg, 0.22 mmole), and sodium bicarbonate (84 mg, 1 mmole). The resulting suspension is protected from
 5 moisture and stirred at 0° for 12 hours. More diphenylphosphonylazide is added (47.5 μ l, 0.22 ml) and stirring continued at 0°C. After 2 days the reaction mixture is filtered and the filtrate concentrated in vacuo. The residue is
 10 chromatographed on silica gel (90:10:1:0.1 chloroform/methanol/water/acetic acid elution) to give 125 mg of the analytical sample as a white solid.

Step B.

15



25

The tri-peptide of Step A. (41 mg, 0.06 mmole) is dissolved in 5 ml of chloroform and the resulting solution is treated with 20 mg of tech. grade m-chloroperbenzoic acid (85%). The reaction mixture is allowed to stand for 19 hours at room
 30 temperature and then the solvent is removed under reduced pressure. The residue is chromatographed on silica gel (chloroform-ethanol-ammonia 80:10:1 elution). The material with R_f value of 0.24 is

41190/1252A

- 120 -

17008IB

5 $R^{1'}$ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl alkyl, heterocyclic, heterocyclic each of which may be substituted with up to three members selected from alkyl, halo, amino and alkoxy groups.

n' is 0 or 1.
 10 $R^{2'}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl, aryl alkyl, heterocyclic, heterocyclic alkyl, each of which may be substituted with up to three members selected from alkyl, hydroxy, halo, amino, alkylamino, dialkylamino, and alkoxy.

15 $R^{3'}$ is OH , NH_2 , $NHR_a^{3'}$, $NR_a^{3'}N_b^{3'}$, $OR_c^{3'}$

20 where $R_a^{3'}$, $R_b^{3'}$, and $R_c^{3'}$ are separately alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl, aryl alkyl, heterocyclic, heterocyclic alkyl, each of which may be substituted with up to three members selected from amino, alkyl amino, dialkyl amino, trialkyl ammonium, hydroxy, alkoxy, aryloxy, aryl alkoxy, or halo.

25 $R_c^{3'}$ may also be $R_d^{3'}-CO-V'-CR_e^{3'}R_f^{3'}$ wherein $R_d^{3'}$ is alkyl or aryl; $R_e^{3'}$ and $R_f^{3'}$ are hydrogen or alkyl; V' is -O- or -NH-.

30 $R^{4'}$ is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, each of which may be substituted with up to three members selected from amino, alkyl amino, dialkyl amin, trialkyl

41190/1252A

- 122 -

170081B

$R^{8'}$ is hydrogen, methyl and cycloalkyl including cyclopentyl and indanyl, such that when $R^{8'}$ is cycloalkyl, $R^{6'}$ and $R^{7'}$ are both hydrogen.

5 $R^{9'}$ is hydroxy, $OR_a^{3'}$, $-NH_2$, $-NHR_a^{3'}$, $NR_a^{3'}R_b^{3'}$, where $R_a^{3'}$ and $R_b^{3'}$ are as defined above, such that when A^* and B^* are both

absent, $R^{9'}$ can be
$$\begin{array}{c} R^{6'} \quad R^{5'} \quad O \\ | \quad | \quad || \\ -N-C-C-R^{3'} \\ | \\ R^{6'} \end{array}$$

10

and pharmaceutically acceptable salts thereof.

In the above definitions, the terms alkyl or alk, alkenyl, alkynyl, include hydrocarbon groups of up to 8 carbon atoms which groups may be straight or branched chain. Preferred alkyl or alk groups have 1-4 carbon atoms. Preferred alkenyl and alkynyl groups have 3 to 6 carbon atoms.

20 The term halo means fluoro, chloro, bromo and iodo.

The term aryl represents hydrocarbon aryl of up to 10 carbon atoms exemplified by phenyl, naphthyl, biphenyl and cycloalkyl-fused derivatives thereof such as indanyl and tetralinyl.

25 The term heterocyclic represents substituted and unsubstituted 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur having varying degrees of unsaturation wherein the nitrogen and sulfur heteroatoms may optionally be oxidized and 30 the nitrogen atom be quaternized, and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring. Heterocyclic

41190/1252A

- 124 -

17008IB

- c) compounds of Formula I, I^a, I^b and I^b
 where 1.) X' is OR₄' and R₄' is
 other than H, and preferably is C₁-C₆
 alkyl or 2.) R₄' in the E° unit is other
 5 than H, and preferably is C₁-C₆ alkyl.

The peptides of the present invention may
 also be described in terms of common amino acid
 components and closely related analogs thereof, in
 accordance with formula (I):



(I)

werein A° has the same meaning as described above:

- 15 A° and B° can each be, for example, Ala, Leu, Phe,
 Tyr, Trp, Met, HomoPhe, BishomoPhe, HomoTyr, HomoTrp,
 3-(1-Naphthyl)Ala, 3-(2-Naphthyl)Ala, 5-MethoxyTrp,
 N-MethylPhe, N-Methyl-HomoPhe, α-methylPhe.

- It will be understood that closely related
 20 analogs of the above common amino acids, for
 examples, aliphatic amino acids in addition to Ala,
 Val, Leu, and Ile, such as alpha amino butyric acid
 (Abu) are included in the broad description of the
 peptides of the present invention represented by
 25 Formula (I) and its definitions.

- In the above definitions, when A° is R°CO,
 and A° is alkyl, aryl, aryl alkyl, heterocyclic or
 heterocyclic alkyl, these groups being optionally
 substituted by amino, C₂-C₆ alkanoylamino,
 30 hydroxy, alkyl, alkoxy, alkoxy carbonyl, halo, or
 nitro; and B° is absent and D° is


41190/1252A

- 126 -

17008IB

Preferred G° substituents include -OH, -OEt, -NH₂.

The amino acid units have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers. All isomeric forms are included in the present peptides. In general, the preferred chiral forms of amino acid units B° and D° are the (L) forms. The stereocenters present in the E° unit of the peptides of Formula I° are in general of the chirality which corresponds to the naturally-occurring (L) amino acids. Thus, for example, the unit E° of the formula below possesses the stereochemistry shown in the preferred form:



The following are illustrative examples of Formula I° peptides:

1. [N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-propionyl)histidyl)-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentylphosphinic acid
2. [N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-propionyl)histidyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid

4119o/1252A

- 128 -

17008IB

14. [N-(N-carbobenzoxy-histidyl)-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentylphosphinic acid
15. [N-(phenylalanyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid
- 5 16. [N-(lysyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid
17. [N-(Nε-1-naphthyloxyacetyl-lysyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid
18. Methyl [N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)propionyl)histidyl)-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentylphosphinate
- 10 19. Methyl [N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)propionyl)histidyl)-1-amino-2-cyclohexylethyl] carbomethoxymethylphosphinate
- 15 20. Ethyl [N-(N-3-phenylpropionyl-phenylalanyl)-1-amino-2-cyclohexylethyl] 2-carbomethoxy-3-methylbutylphosphinate

The Formula I^o compounds include many which bear acidic and/or basic groups; pharmaceutically acceptable salts of these compounds are included. Among the useful acid addition salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinat, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thio-

41190/1252A

- 130 -

17008IB

The novel peptides of Formula I° possess an excellent degree of activity in treating hypertension and congestive heart failure. The Formula I° compounds also are expected to be orally active.

5 For these purposes the compounds of Formula I° may be administered orally, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and
10 vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs,
15 cats, etc., the compounds of the invention are effective in the treatment of humans.

The pharmaceutical compositions containing Formula I° peptides may be provided in oral dosage forms e.g. tablets, capsules, solutions, dispersions,
20 etc., the oral formulations are prepared using conventional procedures and compounding ingredients e.g. carriers, diluents, etc. The compositions may also be in the form of a sterile injectable preparation, for example as a sterile injectable
25 aqueous or oleagenous suspension. This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a
30 non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic

41190/1252A

- 132 -

17008IB

excretion, drug combination and the severity of the particular disease undergoing therapy.

Thus, in accordance with the present invention there is further provided a pharmaceutical composition for treating hypertension and congestive heart failure, comprising a pharmaceutical carrier and a therapeutically effective amount of a peptide of the Formula I°.

Also, in accordance with the present invention there is still further provided a method of treating hypertension and congestive heart failure, comprising administering to a patient in need of such treatment, a therapeutically effective amount of a peptide of the Formula I°.

The renin inhibitory peptides of Formula I° may also be utilized in diagnostic methods for the purpose of establishing the significance of renin as a causative or contributory factor in hypertension or congestive heart failure in a particular patient. For this purpose these peptides may be administered in a single dose of from 0.1 to 10 mg per kg of body weight.

Both in vivo and in vitro methods may be employed. In the in vivo method, a novel peptide of the present invention is administered to a patient, preferably by intravenous injection, although other routes of parenteral administration are also suitable, at a hypotensive dosage level and as a single dose, and there may result a transitory fall in blood pressure. This fall in blood pressure, if it occurs, indicates supranormal plasma renin levels.

Some of the peptides of Formula I, particularly those of Formula I° also have

41190/1252A

- 134 -

17008IB

of dicyclohexylcarbodiimide/1-hydroxybenzotriazole and of disuccinimido oxallate (K. Takeda *et al.*, Tetrahedron Lett., 24, 4451-54 (1983)). In many cases, both carboxylic and phosphonic (or phosphinic esters) may be hydrolyzed along with amino protecting groups as the last step in the synthesis. In these cases, treatment of the phosphorus-containing peptide analog with 30% hydrobromic acid in acetic acid, with 6N hydrochloric acid, or with aqueous sodium hydroxide, followed by purification of the resulting deprotected material by ion-exchange chromatography or reverse-phase HPLC, provides the desired product. In instances where the phosphorus-containing component E possesses a carboxyl-terminal amide function, the fully coupled material A^{*}-B^{*}-D^{*}-E^{*} may be treated with 1 equivalent of lithium hydroxide (0.1 N) to hydrolyze selectively an ester function in E^{*}. Standard coupling procedures may then be used to couple the resulting free carboxylic acid to an appropriate amine. This is followed by removal of the remaining protecting groups as described above. Alternatively the amide formation may be carried out prior to coupling of the component E^{*} to the A^{*}-B^{*}-D^{*} unit.

Preparation of the phosphorus-containing components E are carried out as illustrated in the examples to follow.

The 1-aminoalkylphosphonous acids used as starting materials in the examples below are prepared as illustrated in the examples and can be resolved to give optically active materials by the method of Baylis *et al.* (J. Chem. Soc. Perkin Trans 1, 2845-53 (1984)). Compounds derived from both the optically


41190/1252A

- 136 -


170081B

It will be understood that the following schemes outline representative examples of the preparation of peptides of Formula I and that similar peptides possessing alternative substituents can
5 equally well be prepared by the routes outlined.

The component E° may be, for example, a phosphinic acid of the Formula II.



Peptide VIII containing II may be prepared
20 as outlined in the scheme below:




41190/1252A

- 138 -

17008IB


An alternative procedure for preparation of
phosphate VI is illustrated in the Scheme below:





41190/1252A

- 140 -

170081B



10 Route B:





30

41190/1252A

- 142 -

17008IB

Peptide XXVII containing such a component E
may be prepared as outlined in the following scheme:



25

30

41190/1252A

- 144 -

17008IB

Melting points were recorded on a Thomas-Hoover melting point apparatus and are uncorrected as are all boiling points. ^1H NMR spectra were taken on a Varian XL-300 FT spectrometer. Chemical shifts are reported in ppm downfield from tetramethylsilane as internal standard. IR spectra were recorded on a Perkin-Elmer Model 297 spectrometer. Optical rotations were measured with a Perkin Elmer 141 automatic polarimeter in the solvents indicated. Mass spectra (MS) were taken on a Varian 731 spectrometer at 70 eV. Those marked FAB were taken by using the fast atom bombardment method.

The following examples illustrate preparation of representative compounds, particularly those of Formula I*. All temperatures are in °C unless otherwise noted.

EXAMPLE 1A

20 Cyclohexylacetaldehyde

A suspension of 100 g (0.46 moles) of pyridinium chlorochromate and 100 g of celite in 800 ml of methylene chloride was stirred vigorously while 38 g (0.3 moles) of 2-cyclohexylethanol in 200 ml of methylene chloride was added all at once. The reaction turned dark immediately and became mildly exothermic. After 1 hour, 1000 ml of ether was added and the reaction mixture was filtered through a bed of silica gel (ca. 250 g) on a fritted glass disk. The pad was rinsed with an additional liter of ether. The combined filtrates were reduced in volume to approximately 200 ml and the solution was washed with 2 x 40 ml of 6N HCl, 1 x 50 ml of saturated

41190/1252A

T 146 -

17008IB

The flask was then immersed in an oil bath preheated to 115°C. After 1 hour the reaction was almost homogeneous. After a total of 3 hours at 115°C, the reaction mixture was cooled to 0°C in an ice bath.

5 The solution was washed with 1 x 200 ml and 2 x 100 ml of hexanes. The hexanes wash was discarded and the remaining aqueous acid solution was evaporated to dryness on a rotary evaporator. The resulting semi-crystalline foam was dissolved in 125 ml of

10 absolute ethanol and cooled to 0°C in an ice bath. Propylene oxide (50 ml) was slowly added and a white precipitate was formed. The reaction mixture was allowed to warm to room temperature of its own accord while stirring. After a total of 18 hours, the

15 slurry was cooled to 0°C again, and the solid filtered off. The solid was washed with 100 ml more of ice-cold ethanol and dried to afford 11.98 g (53% overall) of a white solid mp 220-221°C (turns orange and bubbles). NMR (D₂O) (60 MHz): 0.8-2.1 (m,

20 14H); 3.3 (m, 2H); 7.0 (d, J=527 Hz, 1H) ppm.

EXAMPLE 3A

Methyl N-CBZ-1-Amino-2-cyclohexylethylphosphinate

A solution of 7.00 g (0.037 moles) of

25 1-amino-2-cyclohexylethylphosphonous acid in 105 ml of dioxane and 40 ml of 1N NaOH was cooled to 0°C in an ice bath and stirred vigorously while 10.50 ml (12.53 g; 0.073 moles) of benzyl chloroformate and 80 ml of 1N NaOH were added rapidly and simultaneously

30 over a period of approximately 1 minute. The pH was adjusted to the 8-9 range using 1N NaOH (hydrion paper) added in small increments. The reaction mixture was allowed to come to room temperature, and

41190/1252A

- 148 -

17008IB

reaction mixture was allowed to come to room temperature. After a total reaction time of 17 hours, the dioxane was removed in vacuo and the aqueous was acidified with 1N KHSO_4 . The mixture was extracted with 3 x 50 ml of ethyl acetate. The combined ethyl acetate solution was dried (anhydrous Na_2SO_4) and evaporated in vacuo to a slightly cloudy oil.

The oil was redissolved in 50 ml of ethyl acetate and treated with 50 ml of ethereal diazomethane solution. The reaction mixture was stirred at room temperature for 2 hours, then the volatiles were removed completely in vacuo to give a thick oil. The crude product was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant to give 1.17 g (100%) of product as a very thick oil. NMR (CDCl_3) (60 MHz): 0.0-2.2 (m containing 9H s at 1.5, 23H (total)); 3.7, 3.9 (s, 3H); 5.2-6.0 (m, 1H); 6.9 (d, $J=552$ Hz, 1H) ppm.

EXAMPLE 5A

Methyl (N-CBZ-1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinate

A solution of 2.75 g (0.008 moles) of methyl 1-CBZ-amino-2-cyclohexylethylphosphinate in 25 ml of absolute methanol was cooled to 0°C in an ice bath and 4.60 ml of 2M NaOMe in methanol (0.009 moles) was added via syringe. The reaction mixture was stirred at 0°C for 10 minutes, at which time 1.21 g (0.009 moles) of methyl 2-(2-methylpropyl)acrylate was added all at once. The reaction was allowed to proceed at 0°C for 30 minutes, then the ice bath was removed and

41190/1252A

- 150 -

170081B

crude product was purified by silica gel chromatography using ethyl acetate as an eluant to afford 4.77 g (61%) of the product as a very viscous oil. NMR (CDCl_3) (60 MHz): 0.9 (m, 6H); 0.8-2.2 (m, containing 9H s at 1.5, 29H total); 3.6, 3.8 (s, 3H); 3.7 (s, 3H) ppm.

EXAMPLE 7A

10 Methyl (1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinate

A mixture of 1.86 g (0.004 moles) of the ester product of Example 5A and 0.95 g of 10% Pd on carbon in 30 ml of absolute methanol was hydrogenated on a Parr type apparatus at 40 psig of hydrogen for 15 20 hours. The reaction mixture was filtered through a small pad of celite and the pad washed well with methanol. The filtrate was evaporated completely in vacuo to afford the pure free amine (1.34 g; 100%) as a viscous oil. NMR (CDCl_3) (300 MHz) 0.8-1.0 (m, 20 6H); 0.8-3.0 (m, 20H); 3.7-4.0 (series of s, total 6H); 8.1 (very br s, 2H) ppm.

EXAMPLE 8A

25 Methyl (1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinate hydrochloride

A solution of 1.13 g (0.003 moles) of the product of Example 6A in 20 ml of absolute methanol was treated with 12 ml of HCl/methanol (144 g of HCl in 400 ml methanol). The reaction mixture was 30 stirred at room temperature for 4.5 hours. Analysis by thin layer chromatography indicated that no more starting material remained. The volatiles were removed in vacuo and replaced several times with more

41190/1252A

- 152 -

17008IB

EXAMPLE 10A

Methyl [N-(N^{1m}-DNP-histidyl)-1-amino-2-cyclohexyl]
2-carbomethoxy-4-methylpentylphosphinate hydrochloride

5 A solution of 0.949 g (0.0013 moles) of the
product of Example 9A in 10 ml of absolute methanol
was treated with 15 ml of HCl in methanol (144 g
HCl/400 ml methanol). The reaction mixture was
stirred at room temperature for 1 hour. The
volatiles were removed completely in vacuo to afford
10 0.795 g (90%) of the crude product as a brown foam.
NMR (CDCl₃) (300 MHz): 0.8-1.0 (m, 6H); 0.9-2.4
(m, 20H); 2.9 (br s, 2H); 3.2 (m, 1H); 3.7 (br s,
6H); 7.0 (m, 1H); 7.5-7.9 (m, 2H); 8.6 (m, 1H); 8.8
(m, 1H) ppm.

15

EXAMPLE 11A

N-CBZ-2-Amino-3-(1-naphthyl)propionic acid

A solution of 0.700 g (0.003 moles) of
2-amino-3-(1-naphthyl)propionic acid in 10 ml of
20 dioxane and 3.2 ml of 1N NaOH was cooled to 0°C in an
ice bath and 6.40 ml of 1N NaOH and 0.923 ml (1.10 g;
0.0064 moles) of benzyl chloroformate were added
simultaneously and rapidly via syringe. The reaction
mixture was stirred vigorously and the pH was
25 adjusted to the 8-9 range by adding 1N NaOH dropwise.
The reaction was allowed to come to room temperature
of its own accord while stirring vigorously. After
24 hours at room temperature, the dioxane was removed
in vacuo and the aqueous washed with 2 x 10 ml of
30 ether. The ether layers were discarded and the
aqueous layer was acidified to pH=1-2 (hydrion pap r)
using 1N KHSO₄. The aqueous solution was extracted
with 2 x 50 ml of ethyl acetate. The combined ethyl

EXAMPLE 13A

Methyl [N-(N-(N-CBZ-2-amino-3-(1-naphthyl)propionyl)-
N^{1m}-DNP-histidyl)-1-amino-2-cyclohexylethyl] 2-carbo-
methoxy-4-methylpentylphosphinate

- 5 A mixture of 0.176 g (0.0005 moles) of N-CBZ-
2-amino-3-(1'-naphthyl)-propionic acid and .156 g
(0.00055 moles) of disuccinimidyl oxalate in 7 ml of
dry acetonitrile was treated with 0.045 ml (0.00055
moles) of dry pyridine. The reaction mixture was
10 stirred at room temperature under nitrogen atmosphere
for 20 hours. The mixture became homogeneous during
this period. At this time, a solution of 0.300 g
(0.00043 moles) of the product of Example 10 in a
mixture of 8 ml of dry acetonitrile and 0.28 ml
15 (0.202 g) of triethylamine was added all at once.
The reaction turned very dark and stirring at room
temperature under nitrogen was continued for 20
hours. The volatiles were evaporated in vacuo and
the residue added to 30 ml of ethyl acetate, which
20 was washed with 2 x 10 ml of saturated NaHCO₃,
dried over anhydrous Na₂SO₄, filtered, and the
volatiles removed in vacuo. The residue was chromato-
graphed on silica gel using 18:1:1 methylene
chloride:acetone:methanol as the eluant to afford
25 0.348 g (86%) of the tripeptide as a brownish-yellow
glassy foam. NMR (CDCl₃) (300 MHz): 0.7-0.9 (m,
6H); 0.9-2.3 (m, 20H); 2.8-3.5 (m, 3H); 3.5-3.8
(series of singlets, total=6H); 4.1-4.8 (m, 2H); 5.0
(s, 2H); 5.3-5.6 (m, 1H); 6.8-7.6 (m, 14H); 7.8 (t,
30 1H); 7.9 (t, 1H); 8.2 (d, 1H); 8.5 (br, t, 1H); 8.8
(s, 1H) ppm.

41190/1252A

- 156 -

17008IB

EXAMPLE 15A

Methyl [N-(N-(N-CBZ-2-amino-3-(1-naphthyl)propionyl)-histidyl-1-amino-2-cyclohexylethyl] 2-carbomethoxy-4-methylpentylphosphinate

- 5 A solution of 0.100 g (0.0001 moles) of the product of Example 13 in 4 ml of dry DMF was put in a Fisher-Porter tube and approximately 20 ml of ammonia was condensed into the tube also. The reaction turned dark purple. The tube was sealed and stirring
10 was continued for approximately 3 hours. During this time the color went from purple to pink. The tube was opened and the ammonia was allowed to evaporate. The remaining solution was transferred to a flask and the volatiles were removed completely in vacuo. The
15 residue was chromatographed on silica gel, giving 0.018 g (22%) of the desired product as a light yellow oil. NMR (CDCl₃) (300 MHz): 0.8-1.0 (m, 6H); 1.0-1.8 (m, 23H); 1.9-3.4 (m, 2H); 2.8-3.1 (m, 1H); 3.4 (m, 1H); 3.7-3.8 (series of singlets,
20 total=6H); 4.6 (m, 1H); 5.1 (s, 1H); 5.2 (br s, 2H); 5.6 (m, 1H); 7.2-7.7 (m, 11H); 7.8 (d, 1H); 7.9 (d, 1H); 8.3 (br d, 1H) ppm.

EXAMPLE 16A

- 25 [N-(N-(N-CBZ-2-amino-3-(1-naphthyl)propionyl)histidyl-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentyl-phosphinic acid disodium salt

- A solution of 0.018 g (0.000022 moles) of the product of Example 15A in 1 ml of ethanol was
30 treated with 0.44 ml of 0.10N NaOH solution (0.000044 moles). The reaction mixture was stirred at room temperature for 16 hours. The volatiles were vaporated completely in vacuo and the residue

41190/1252A

-,158 -

17008IB

again immediately thereafter. Heating at 100°C was continued for a period of 4 hours. At this time, the reaction mixture was cooled to 0°C in an ice bath, and the solid filtered off and washed with 3 x 10 ml portions of ice-cold ethanol. The solid was dried in
5 vacuo to afford 11.00 g of solid product as a fluffy white powder.

The crude powder was dissolved in 120 ml of trifluoroacetic acid, and the resulting solution was
10 heated to 100°C in an oil bath. After approximately 5 minutes, the reaction had turned dark purple. Heating was continued for 1 hour. The reaction mixture was cooled to room temperature and the residue was partitioned between 250 ml of water and
15 100 ml of ether. The ether layer was separated and the aqueous washed with another 100 ml of ether. The ether was discarded and the aqueous solution evaporated completely in vacuo. The remaining white solid was treated with 10 x 50 ml of methanol, each
20 time evaporating the methanol on a rotary evaporator. The white solid that remained was triturated with 25 ml of anhydrous ether to afford 3.77 g (36% overall) of the desired product. NMR (D₂O) (60 MHz):
1.0-2.4 (m, 9H); 3.2 (m, 1H); 5.4-5.8 (m, 2H); 6.9
25 (d, J=528Hz, 1H) ppm.

EXAMPLE 20A

Methyl N-CBZ-1-amino-2-(1,2,3,6-tetrahydrophenyl)-
ethylphosphinate

30 A solution of 2.50 g (0.013 moles) of 1-amino-2-(1,2,3,6-tetrahydrophenyl)ethylphosphonous acid in 15 ml of 1N NaOH and 30 ml of dioxane that had been cooled to 0°C in an ic bath was stirred

41190/1252A

- 160 -

170081B

acid in 16 ml of dioxane and 16 ml of 0.5N NaOH was cooled to 0°C in an ice bath, whereupon 2.00 ml (1.90 g; 0.0087 moles) of di-tert-butyl dicarbonate was added all at once. The reaction mixture was stirred vigorously at 0°C for 5 minutes, then removed from the ice bath and stirred at room temperature for 3 hours. The dioxane was removed in vacuo and the aqueous solution acidified to pH=1-2 (hydrion paper) with 1N KHSO₄. The mixture was extracted with 2 x 75 ml of ethyl acetate. The combined ethyl acetate was dried over anhydrous Na₂SO₄, filtered, and the volatiles evaporated in vacuo to give a viscous oil.

The residual oil was dissolved in 50 ml of ethyl acetate and treated with 40 ml of ethereal diazomethane solution. The reaction mixture was stirred at room temperature for 1 hour and 10 minutes, then the volatiles were evaporated completely in vacuo. The residual oil was chromatographed on silica gel using 25:1:1 methylene chloride:acetone: methanol to afford 1.83 g (95%) of the product as a very thick yellow oil that crystallized very slowly. NMR (CDCl₃) (60 MHz): 1.0-2.2 (m containing 9H s at 1.4, total=19H); 3.7, 3.9 (singlets, total=3H); 3.9-4.2 (m, 1H); 5.0-5.7 (m, 2H) ppm.

EXAMPLE 22A

Methyl [N-BOC-1-amino-2-(1,2,3,6-tetrahydro)phenyl-ethyl] 2-carbomethoxy-4-methylpentylphosphinate

A solution of 0.700 g (0.003 moles) of the product of Example 21A in 5 ml of absolute methanol was cooled to 0°C whereupon 1.65 ml (0.0033 moles) of 2N NaOMe in methanol was added over a on minut

41190/1252A

- 162 -

170081B

EXAMPLE 24A

Methyl [N-(N-BOC-glycylglycyl)-1-amino-2-(1,2,3,6-tetrahydro)phenylethyl] 2-carbomethoxy-4-methylpentyl-phosphinate

- 5 A suspension of 0.202 g (0.00087 moles) of N-BOC-glycylglycine and 0.272 g (0.00096 moles) of disuccinimidyl oxalate in 13 ml of dry acetonitrile was treated with 0.078 ml (0.076 g; 0.00096 moles) of dry pyridine. The heterogeneous mixture was stirred
- 10 at room temperature under nitrogen atmosphere and slowly became homogeneous over a period of several hours. The reaction was stirred at room temperature for a total for 17 hours. At this time, a solution of the product of Example 23 in 14 ml of acetonitrile
- 15 containing 0.484 ml (0.352 g; 0.0035 moles) of triethylamine was added all in one portion. The reaction mixture was allowed to stir at room temperature under nitrogen atmosphere for 48 hours. At this time the volatiles were evaporated in vacuo
- 20 and the residue dissolved in 30 ml of ethyl acetate. The organic solution was washed with 2 x 20 ml of saturated NaHCO_3 , dried over anhydrous Na_2SO_4 , filtered, and the volatiles removed in vacuo. The residue was purified by silica gel chromatography
- 25 using 18:1:1 methylene chloride:acetone:methanol as the eluant to afford the product as a light yellow oil. NMR (CDCl_3) (300 MHz): 0.8-1.0 (m, 6H); 1.1-1.9 (m containing 9H s at 1.5, total=22H); 1.9 (br s, 1H); 2.2 (m, 1H); 2.9 (m, 1H); 3.6-3.8 (series
- 30 of singlets; total=6H); 3.7-4.2 (m, 4H); 4.5 (m, 1H); 5.3-5.8 (m, 2H); 6.7-7.2 (m, 2H) ppm.

41190/1252A

- 164 -

17008IB

was treated with HCl gas for 45 minutes. The reaction was allowed to stand overnight and then filtered to remove a small amount of solid material. The remaining 29.15 g (0.084 moles) of starting material was dissolved in 430 ml of anhydrous ether and treated similarly. The combined filtrates from the two reactions was evaporated in vacuo and the viscous oil treated with several 200 ml portions of carbon tetrachloride followed by evaporation in vacuo. This procedure led to a sticky crystalline mass which was triturated with anhydrous ethyl ether and filtered and then vacuum dried to afford 41.55 g (64%) of the salt as a white crystalline solid. NMR (CDCl₃) (60 MHz): 1.0-1.6 (m, 6H); 2.1 (s, 2H); 3.2-4.5 (m, 9H); 7.2 (s, 10H) ppm.

EXAMPLE 27A

Diethyl 2-Amino-3-phenylethylphosphonate hydrochloride

A solution of 2.00 g (0.0052 moles) of the product of Example 26A in 8 ml of absolute ethanol containing 0.200 g of 10% Pd on carbon was hydrogenated in a Parr type apparatus for 7 hours at 40 psig of hydrogen. The reaction mixture was filtered through a celite pad and the pad washed well with ethanol. The combined filtrates were evaporated in vacuo to give 1.50 g (99%) of the product as a very viscous, colorless oil. NMR (d₂-acetone) (60 MHz): 1.0-1.6 (overlapping t, 6H); 3.3-5.0 (m, 7H); 7.0-7.6 (m, 5H) ppm.

30

41190/1252A

- 166 -

170081B

cyclohexylacetaldehyde (7.2 g, 0.057 mol). After stirring for 30 minutes at 0°C and 2 hours at room temperature, the reaction was filtered and the solvents removed by evaporation in vacuo. The residue was redissolved in 100 ml of dichloromethane cooled to 0°C and esterified with an ether solution of diazomethane. The solvents and excess diazomethane were subsequently removed by evaporation in vacuo and the crude product was purified by chromatography to give 11 g of the title compound.

Chromatography: silica, ethyl acetate
TLC (silica, ethyl acetate) $R_f=0.48$
NMR (CDCl₃, TMS) 0.9-2.0 (m, 13H), 2.95 (d 16Hz, 2H), 3.64 (s, 3H), 3.7 (d 12Hz, 3H), 3.9-4.5 (m, 1H), 5.1 (s, 2H), 5.4 and 5.8 (d 10Hz, 1H), 7.2 (s, 5H)
mass spectrum: M^+

EXAMPLE 31A

Methyl (N-CBZ-1-amino-3-methylbutyl) carbomethoxy-methylphosphinate

This ester is prepared by the procedure described in Example 33A, using 3-methylbutyraldehyde in place of cyclohexylacetaldehyde. It can also be prepared by the method of P. A. Bartlett et al., J. Amer. Chem. Soc., 106, 4282-83 (1984).

EXAMPLE 32A

N-CBZ-1-aminoethylphosphinic acid

The title compound was prepared using the procedure described in Example 2A with paraldehyde replacing hexahydrophenylacetaldehyde.

41190/1252A

- 168 -

17008IB

products were isolated; fraction A (0.190 g, 0.43 mmol, 26%) and fraction B (0.217 g, 0.49 mmol, 30%). Product A, which eluted from the column first, was identified as the E isomer by analysis of its 300 MHz
5 proton NMR spectrum (olefinic proton resonance at 6.68 ppm (CDCl₃). Product B is the Z isomer (olefinic proton resonance at 6.03 ppm).
Anal. Calcd for C₂₂H₄₀NO₆P:
C, 59.31; H, 9.05; N, 3.14.
10 Found: (Fraction A) C, 59.07; H, 8.86; N, 3.08;
(Fraction B) C, 59.47; H, 8.82; N, 3.15.
MS (FAB) 446 (both isomers) (M⁺ +1).

EXAMPLE 34A

15 Methyl 2-(2-methylpropyl)acrylate

This compound was prepared by the method of J. Harley-Mason et al. (Tetrahedron 1980, 36, 1063) in approximately 35% overall yield. NMR (CDCl₃) (300 MHz): 0.9 (d, 6H); 1.8 (septet, 1H); 2.2 (d,
20 2H); 3.7 (s, 3H); 5.5 (d, 1H); 6.1 (d, 1H) ppm.

EXAMPLE 35A

Methyl 2-(cyclohexylmethyl)acrylate

This compound was prepared as above in
25 approximately 20% overall yield from dimethyl malonate and bromomethylcyclohexane. NMR (CDCl₃) (60 MHz): 0.8-2.0 (m, 11H); 2.2 (d, 2H); 3.7 (s, 3H); 5.4 (m, 1H); 6.0 (d, J=2Hz, 1H) ppm.

EXAMPLE 36A

30 Methyl 2-(n-propyl)acrylate

This compound was prepared as above in approximately 45% overall yield from dimethyl

41190/1252A

- 170 -

170081B

crystalline solid. 28H); 2.7-3.2 (m, 6H); 3.5-3.8 (m, 6H); 4.1-5.4 (m, 3H); 6.8-7.6 (m, 6H); 7.6-7.9 (m, 2H); 8.0 (br s, 1H) ppm.

5

EXAMPLE 39A

Methyl (N-CBZ-1-amino-2-cyclohexyl)2-carbomethoxy-3-cyclohexylpropylphosphinate

A solution of 3.39 g (0.010 moles) of the product of Example 3A in 25 ml of absolute methanol was cooled to 0°C under N₂. At this time, a solution of 5.50 ml of 2N NaOMe in methanol was added dropwise over a period of ca. 1 min. The reaction mixture was stirred for 10 min. and at this time, 1.91 g (0.0105 moles) of the product of Example 35 was added over a 1 min. period. The reaction mixture was stirred at 0°C for 30 min., then at room temperature for 23 hours. The volatiles were removed in vacuo and the residue added to 50 ml of ice-cold 1N HCl. The mixture was extracted with 3 X 50 ml of ethyl acetate. The combined ethyl acetate was dried over anh. MgSO₄, filtered, and the volatiles evaporated in vacuo to a colorless oil. The residue was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant to afford 4.26 g (82%) of the desired product as a very viscous oil. NMR (CDCl₃) (300 MHz): 0.7-1.9 (m, 28H); 2.1 (m, 1H); 2.9 (br s, 1H); 3.6-3.8 (m, 6H); 4.1 (br s, 1H); 5.1 (s, 2H); 7.3 (s, 5H) ppm.

30

EXAMPLE 40A

Methyl (1-amino-2-cyclohexyl)2-carbomethoxy-3-cyclohexylpropylphosphinate

A mixture of 4.00 g (7.7 mmol) of the product of Example 39 in 50 ml of absolute methanol

41190/1252A

-, 172 -

170081B

volatiles evaporated in vacuo. The residue was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant to afford 2.69 g (65%) of the desired product as a viscous dark yellow oil. NMR (CDCl₃) (300 MHz): 0.7-1.9 (m containing 9H s at 1.4, 37H); 2.8 (br s, 1H); 3.1 (m, 1H); 3.7 (m, 6H); 4.4 (br s, 1H); 6.0 (m, 1H); 7.0 (m, 1H); 7.5-8.0 (m, 2H); 8.6 (dd, 1H); 8.9 (s, 1H) ppm.

10

EXAMPLE 42A

Methyl [N-(N^{im}-DNP-histidyl)-1-amino-2-cyclohexylethyl] 2-carbomethoxy-3-cyclo-hexylpropylphosphinate

A solution of 2.00 g (2.6 mmol) of the product of Example 41A in 20 ml of methanol was treated all at once with 20 ml of HCl in methanol (134.4 g of HCl in 400 ml of methanol). The reaction mixture was stirred at room temperature for 1 hour 15 minutes. The volatiles were removed completely in vacuo, and the residue triturated with 2 X 15 ml of anhydrous ether to afford 1.83 g (99%) of the desired product. NMR (CDCl₃) (300 MHz): 0.7-2.0 (m, 28H); 2.2 (m, 1H); 2.8 (m, 1H); 3.4-3.9 (m, 6H); 4.3 (br s, 1H); 4.8 (br s, 1H); 7.4-9.6 (m, 8H) ppm.

25

EXAMPLE 43A

Methyl [N-(N-(N-CBZ-2-amino-3-(1-naphthyl)propionyl)-N^{im}-DNP-histidyl)-1-amino-2-cyclohexylethyl] 2-carbomethoxy-3-cyclohexylpropylphosphinate

A mixture of 0.353 g (1.00 mmol) of the product of Example 11A and 0.312 g (1.1 mmol) of disuccinimidyl oxalate in 10 ml of dry acetonitrile was treated with 0.087 g (0.09 ml; 1.1 mmol) of

30

41190/1252A

- 174 -

170081B

homogeneous. At this time, a mixture of 0.727 g (1.00 mmol) of the product of Example 42 and 0.404 g (4.00 mmol; 0.56 ml) of triethylamine in 10 ml of acetonitrile was added all at once. The reaction mixture turned darker and stirring at room temperature under N_2 was continued for 24 hours. At this time, the volatiles were removed in vacuo and the residue dissolved in 50 ml of methylene chloride. The organic solution was washed with 2 X 50 ml of saturated $NaHCO_3$, dried over anhydrous Na_2SO_4 , filtered, and the volatiles removed in vacuo. The residue was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant to give 0.571 g (58%) of the desired product as a glassy foam. NMR ($CDCl_3$) (300 MHz)-: 0.7-1.9 (m, containing 9H s at 1.2, 37H); 2.7-3.3 (m, 4H); 3.5-3.8 (m, 6H); 4.4 (m, 3H); 4.7 (m, 1H); 5.0 (m, 1H); 6.8-8.0 (m, 9H); 8.2 (d, 2H); 8.6 (dd, 2H); 8.8 (t, 1H) ppm.

EXAMPLE 45A

Methyl [N-(N-(N-CBZ-2-amino-4-phenylbutyryl)- N^{im} -DNP-histidyl)-1-amino-2-cyclo-hexylethyl] 2-carbo-methoxy-4-methylpentylphosphate

A mixture of 0.313 g (1.00 mmol) of N-CBZ-2-amino-4-phenylbutyric acid and 0.312 g (1.1 mmol) of disuccinimidyl oxalate in 20 ml of dry acetonitrile was treated with 0.087 g (1.1 mmol; 0.90 ml) of pyridine. The reaction mixture was stirred at room temperature under N_2 for 24 hours. During this period the reaction went from heterogeneous to homogeneous. At this time a mixture of 0.687 g (0.001 moles) of the product of Example 10 and 404 mg

41190/1252A

r 176 -

17008IB

stirred at room temperature under N_2 for 30 hours. The volatiles were removed in vacuo and the residue was dissolved in 50 ml of methylene chloride. The organic mixture was washed with 2 X 15 ml of saturated $NaHCO_3$, dried over anhydrous Na_2SO_4 , filtered, and the volatiles evaporated in vacuo. The residue was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant. This provided 0.493 g (54%) of the desired product as a glassy foam. NMR ($CDCl_3$) (300 MHz): 0.7-1.0 (m, 6H); 1.0-2.2 (m containing 9H s at 1.5, 2.8H), 2.6 (m, 2H); 2.7-3.3 (m, 3H); 3.5-3.8 (m, 8H); 4.0 (m, 2H); 4.4 (m, 1H); 4.7 (m, 1H); 5.0 (m, 1H); 6.9-8.0 (m, 7H); 8.5 (m, 2H); 8.8 (m, 1H) ppm.

15

EXAMPLE 47A

Methyl [N-(N-(N-CBZ-phenylalanyl)- N^{im} -DNP-histidyl)-1-amino-2-cyclohexylethyl]-2-carbomethoxy-4-methylpentylphosphinate

20 A mixture of 0.156 g (0.55 mmol) of disuccinimidyl oxalate and 0.150 g (0.0005 moles) of N-CBZ-phenylalanine in 10 ml of dry acetonitrile was treated with 0.04 ml (0.5 mmol) of pyridine. The reaction mixture was stirred at room temperature under N_2 for 2 hours. At this time, an additional 0.010 g of disuccinimidyl oxalate was added and stirring under N_2 continued for 5 hours. During this time the mixture went from heterogeneous to homogeneous. At this time, 0.330 g the product of Example 10 was added, immediately followed by 0.202 g (2.00 mmol; 0.28 ml) of triethylamine. The reaction mixture immediately turned darker. The mixture was stirred at room temperature for 18h. At this time

30

41190/1252A

- 178 -

17008IB

volatiles were evaporated completely in vacuo and the residue dissolved in 20 ml of ethyl acetate. The organic solution was washed with 3 X 15 ml of saturated NaHCO_3 , dried over anhydrous Na_2SO_4 ,
5 filtered and the ethyl acetate evaporated in vacuo. The residue was chromatographed on silica gel using 18:1:1 methylene chloride:acetone:methanol as the eluant to afford 0.266 g (61%) of the desired product as a glassy foam. NMR (CDCl_3) (300 MHz): 0.7-0.9
10 (m, 6H); 0.9-2.0 (m containing 3H s at 1.3, 26H); 2.5-3.5 (m, 5H); 3.5-3.7 (m, 6H); 4.0 (br s, 1H); 4.3 (br s, 2H); 4.7 (br s, 1H); 5.0 (m, 1H); 6.8-7.0 (m, 2H); 7.0-7.3 (m, 5H); 7.5-8.0 (m, 2H); 8.6 (m, 2H); 8.9 (m, 1H) ppm.

15

EXAMPLE 49A

[N-(N-2-Amino-3-(1-naphthyl)propionyl-histidyl)-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentyl-phosphinic acid

20 A solution of 0.045 g (0.055 mmol) of the product of Example 13A in 3 ml of ethanol was treated with 1.10 ml of 0.100N NaOH (aq.). The reaction mixture was stirred at room temperature for 20 hours, at which time an additional 1.00 ml of 0.100N NaOH
25 was added. Stirring was continued for 1 hour, then the volatiles were evaporated completely in vacuo. The residue was triturated with 3 X 2 ml of anhydrous ether, and the residue was purified by passing it through a column containing ca. 15 g of DOWEX 50W-X4
30 hydrogen form ion-exchange resin (5.2 meq/dry gram). This afforded 0.007 g (15%) of the desired product as a very light yellow glassy foam. NMR (CD_3OD) (300 MHz): 0.6-0.9 (m, 6H); 1.1-2.0 (m, 20H); 2.7 (m, 2H);

41190/1252A

, - 180 -

17008IB

own accord. The remaining volatiles were evaporated completely in vacuo and the residue triturated with anhydrous ether until a free flowing crystalline solid was obtained.

5

EXAMPLE 52A

Methyl [N-(N-(N-CBZ-2-amino-4-phenyl)butyryl-histidyl)-1-amino-2-cyclohexyl-ethyl] 2-carbomethoxy-4-methylpentylphosphinate

10

A solution of 0.200 g (0.21 mmol) of the product of Example 45A in 2 ml of dry dimethylformamide was treated with ca. 12 ml of anhydrous ammonia in a Fisher-Porter Tube. The tube was sealed and the reaction mixture stirred at room temperature for 21 hours. During this period the color of the reaction went from dark purple to reddish-brown. At this time the tube was opened and the ammonia allowed to evaporate of its own accord. The remaining volatiles were evaporated completely in vacuo and the residue was triturated with anhydrous ether until a free flowing solid was obtained.

15

20

EXAMPLE 53A

Methyl [N-(N-(N-BOC-2-amino-4-phenyl)butyryl-histidyl)-1-amino-2-cyclohexylethyl] 2-carbomethoxy-4-methylpentylphosphinate

25

A solution of 0.200 g (0.22 mmol) of the product of Example 46A in 2 ml of dry methylformamide was treated with ca. 12 ml of anhydrous ammonia in a Fisher-Porter Tube. The tube was sealed and the reaction mixture stirred at room temperature for 21 hours. During this period the color of the reaction went from dark purple to reddish-brown. At this time

30

41190/1252A

, - 182 -

17008IB

remaining volatiles were evaporated completely in vacuo and the residue triturated with anhydrous ether. This afforded the desired product as a yellow solid after purification by chromatography on DOWEX
5 50W-X4.

EXAMPLE 56AN-Methyl 1-amino-2-cyclohexylphosphinic acid

This acid is prepared using the procedure
10 described in Example 2A with methylamine hydrochloride replacing aminophenylmethane hydrochloride.

EXAMPLE 57A

15 Methyl N-CBZ-N-methyl 1-amino-2-cyclohexylethyl-phosphinate

This ester is prepared from N-methyl-1-amino-2-cyclohexylphosphinic acid using the procedure described in Example 3A.

20

EXAMPLE 58ADiethyl N-methyl-1-amino-2-phenylethylphosphonate

This ester is prepared using the procedure described in Example 25A with equimolar amounts of
25 methyl amine hydrochloride and triethylamine substituted for benzylamine.

EXAMPLE 59A

30 Diethyl N-CBZ-N-methyl-1-amino-2-cyclohexylethyl-phosphonate

This ester is prepared by treatment of the product of Example 58A with benzyl chloroformate and Et₃N in CH₂Cl₂ and is purified by silica gel chromatography.

41190/1252A

- 184 -

170081B

EXAMPLE 62A

(1-Amino-2-cyclohexylethyl) 2-carbomethoxy-4-methyl-
pentylphosphinic acid

To the product of Example 8 (60 mg; 0.158
5 mmol) was added HBr-HOAc solution (5 equivalents) and
an equivalent volume of HOAc. The solution was
stirred for 24 hours and then concentrated to
dryness, giving the product (40 mg; 61%). MS: m/e
334 ($M^+ + 1$). NMR (D_2O): 0.6-2.3 (22H, m); 2.8
10 (1H, br s); 3.7 (3H, m); 3.3-3.6 (1H, m); 4.2 (1H,
m); 8.0 (3H, br s).

EXAMPLE 63A

Methyl [N-(N-t-butoxycarbonyl-phenylalanyl)-1-amino-
15 2-cyclohexylethyl] 2-carbomethoxy-4-methylpentyl-
phosphinate

The product of Example 8A (0.26 g) was
dissolved in dry CH_2Cl_2 (3 ml) and neutralized
with Et_3N (0.095 ml) at 0°C. To the above solution
20 were added sequentially N-Boc-phenylalanine (0.22 g),
HOBT (0.18 g) and DCC (0.19 g). The mixture after
stirring for 4 hours at 0°C was stirred at 25°C for
an additional 15 hours. The mixture was filtered,
and the CH_2Cl_2 phase was washed with $NaHCO_3$
25 (saturated), water, saturated NaCl and dried
($MgSO_4$). Removal of solvent in vacuo gave a foam
which was purified by medium pressure liquid
chromatography (mplc) using ethyl acetate-hexane
(3:1) on a silica gel column yield 0.28 g (70%)
30 (foam). NMR ($CDCl_3$): 7.23 (5H, s), 6.62 (1H,
m), 5.15 (1H, m), 4.1-4.41 (2H, m), 3.63 (6H, m),
3.11 (2H, m), 2.85 (2H, m), 0.85-2.05 (32H, m). MS
(FAB): m/e 595 ($M^+ + 1$).

41190/1252A

- 186 -

17008IB

EXAMPLE 66A

[N-(Lysyl)-1-amino-2-cyclohexylethyl] 2- carboxy-4-
methylpentylphosphinic acid

The product of Example 65A (60 mg) was
5 stirred with aqueous 1N NaOH (0.18 ml) in acetone (1
ml) for 24 hours. Removal of acetone in vacuo and
acidification with cold 1N HCl gave the free acid as
an oil. The oil was then treated with HBr-AcOH (33%)
(1 ml) for 12 hours at 25°C. Excess HBr was removed
10 in vacuo, and the product was precipitated with dry
ether. The hygroscopic solid was filtered and
dissolved in MeOH (1 ml), and treated with propylene
oxide (0.2 ml). The product was finally precipitated
with dry ether. The solid was filtered, washed with
15 dry ether and dried to give white powder (39 mg).
NMR (CD₃OD): 4.18 (2H, m), 2.85 (2H, m),
0.85-2.15 (29H, m). MS (FAB): m/e 498 (M⁺ +1).

EXAMPLE 67A

20 Methyl [N-(Na-(N-BOC-2-amino-3-(1-naphthyl)propionyl)-
N-CBZ-lysyl)-1-amino-2-cyclohexylethyl] 2-carbo-
methoxy-4-methylpentylphosphinate

The product of Example 65A (0.25 g) was
dissolved in 50% TFA in CH₂Cl₂ (2 ml), and the
25 mixture was stirred at 25°C for 1-1/2 hours. Removal
of excess reagent and CH₂Cl₂ in vacuo gave an oil
which upon drying over P₂O₅ and NaOH in vacuo
gave the amine salt as a foam.

The above foam was dissolved in EtOAc (10
30 ml) and neutralized with saturated NaHCO₃ (aqueous).
The EtOAc phase was washed with brine and dried over
(Na₂SO₄). Removal of solvent in vacuo gave the
free amine as an oil. The free amine was then coupled

41190/1252A

- 188 -

17008IB

hours at 40 psi. The catalyst was filtered off and the filtrate upon evaporation in vacuo gave the pure product as the acetate salt (40 mg). NMR (CDCl_3):

6.95-8.1 (11H, m), 5.60 (1H, d), 5.22 (1H, m), 4.51 (2H, m), 4.12 (1H, m), 3.68 (6H, m), 2.6-2.95 (4H, m), 2.05 (3H, s), 0.85-2.15 (39H, m). MS (FAB): m/e 773 ($\text{M}^+ + 1$).

EXAMPLE 70A

10 Methyl (1-amino-2-cyclohexylethyl)carbomethoxymethylphosphinate hydrochloride

The product of Example 30A (3.58 g) was hydrogenated in methanol (30 ml) [containing concentrated HCl (0.72 ml)] over Pd-C (10%) (0.35 g) at 40 psi overnight at 25°C. The catalyst was filtered off and the filtrate was evaporated to give the product as glass-like solid foam (2.67 g) (94%). MS (FAB): m/e 278 ($\text{M}^+ + 1$).

EXAMPLE 71A

20 Methyl [(N-BOC-phenylalanyl)-1-amino-2-cyclohexylethyl] carbomethoxymethylphosphinate

The product of Example 70A (0.78 g) was treated with Et_3N (0.35 ml) in a mixture of THF- CH_2Cl_2 (1:1) (6 ml) at 0°C. The free amine, thus obtained, was coupled with N-BOC-phenylalanine (0.66 g) in presence of DCC (0.56 g) and HOBT (0.5 g) under standard condition. Filtration and processing of the filtrate gave the crude product as a foam which was purified by flash chromatography on silica gel using 10% hexane in ethyl acetate. Yield (1.18 g) (91%) (foam). MS: $\text{M} + \text{H} = 525$, $\text{M} - 99 = 425$ (-BOC). ^1H NMR: 7.35-7.15 (5H, m), 5.15 (1H, br s), 4.90

41190/1252A

+ 190 -

17008IB

(2H, s), 4.6 (1H, m), 4.05 (1H, m), 3.85-3.60 (6H, m), 3.2 (2H, brs), (2H, d, J=10), 1.90-.8 (19H, m), 1.60, 1.40 (9H, s). MS (FAB): m/e 640 (M^+ +1).

5

EXAMPLE 74A

Methyl [N-(N α -BOC-lysyl)-1-amino-2-cyclohexylethyl] carbomethoxymethylphosphinate

The product of Example 73A (60 mg) was hydrogenated over Pd/C (10%) in MeOH (5 ml) containing 1 equivalent of acetic acid under standard conditions to give the titled compound as a foam (51 mg). NMR (CDCl₃): 8.5 (3H, br s), 8.2-7.6 (1H, m), 5.9-5.5 (1H, m), 4.5 (1H, m), 4.1 (1H, br s), 3.7 (6H, m), 3.2-2.8 (4H, m), 2.0 (3H, s), 1.90-.7 (19H, m), 1.4 (9H, s). MS: m/e 506 (M^+ +1).

EXAMPLE 75A

Methyl [N-(N-(2-naphthyloxy)acetyl-phenylalanyl)-1-amino-2-cyclohexylethyl] carbomethoxymethylphosphinate

The product of Example 71A (0.395 g) was treated with trifluoroacetic acid -CH₂Cl₂ (1:1) (5 ml) at 25°C for 2 hours. Removal of excess reagent in vacuo gave the trifluoroacetate salt of the free amine as a foam, which was dissolved in dry THF (5 ml) and neutralized with Et₃N (0.12 ml). To the free amine, thus obtained, (2-naphthoxy)-acetic acid N-hydroxysuccinimide ester (0.31 g) was added, and the mixture was stirred at 25°C for 24 hours. The crude product obtained, after removal of solvent in vacuo, was purified by mpls using 25% hexane in ethyl acetate. Yield 0.34 g (65%) (foam). MS: M+H = 609. ¹H NMR: 7.8-7.0 (12H, m), 6.9 (1H,

41190/1252A

, - 192 -

17008IB

the corresponding trifluoroacetate salt of the amine was obtained as described before. The salt was dissolved in dry THF (4 ml), neutralized with Et₃N (0.05 ml) and coupled with N-CBZ-β-naphthylalanine (0.125 g) in the presence of HOBT (0.072 g) and DCC (0.081 g) under standard conditions. The reaction was filtered, and the filtrate was washed with saturated NaHCO₃, water and dried (MgSO₄). Removal of the solvent gave an oil which was purified by mpic using 20% hexane in ethyl acetate. Yield 0.21 (68%). ¹H NMR: 8.3-7.1 (17H, m), 7.0-5.2 (4H, m), 5.1 (4H, m), 4.4-4.0 (2H, m), 4.5 (2H, m), 3.8-3.4 (6H, m), 3.1-2.8 (4H, m), 1.9-.6 (19H, m).

Claims to the invention follow.


4119o/1252A

-,194 -

17008IB

where R^1 is as defined further below;


D is absent; or



, where Z is

$-(CH_2)_1-$ and 1 is 1 or 2; or $-S-$;


E is absent; or



, where m is 1 to 4; and

R^5 is hydrogen; C_{1-4} alkyl; aryl; aryl- C_{1-4} alkyl; aryl C_{1-4} alkyl or aryl where the aryl portion is substituted with up to three members selected from the group consisting of C_{1-4} alkyl, trifluoromethyl, hydroxy, C_{1-4} alkoxy, and halo; or indolyl;

G is (1)




. where q is 1 to 4;

X is O, or H, H;

R^4 is hydrogen; or $CH-R^9$,



where R^9 is hydrogen; C_{1-4} alkyl; hydroxy, or C_{3-7} cycloalkyl; and R^3 is hydrogen; C_{1-4} alkyl; aryl; aryl C_{1-4} alkyl; aryl C_{1-4} alkyl or aryl substituted with up to three members selected from the group consisting of C_{1-4} alkyl, trifluoromethyl, hydroxy, C_{1-4} alkoxy, and halo; or indolyl;




41190/1252A

- 196 -

17008IB

and V' is -O- or -NH-; amino; or mono-
or di-C₁₋₄ alkyl amino; and W' is
absent; -O-; -NH-; or -CH₂-;

5



where X'' and X''' are independently

10

absent; or $\overset{\text{O}}{\underset{\uparrow}{\text{S}}}$; and

W'' is absent; -CH₂-; or $\overset{\text{R}^8}{\text{CH-}}$,
where R⁸ is hydrogen or C₁₋₃
alkyl;

15



20




; where R is hydrogen; C₁₋₄
alkyl; formyl; C₁₋₄
alkanoyl; aroyl; carboxy;
C₁₋₄ alkoxy carbonyl; aryl-
oxy carbonyl; or aryl C₁₋₄
alkoxy carbonyl; or

25

(2)

30




where q is 1 to 4;
q' is 0 to 4;
X is O or H, H;

41190/1252A

- 198 -

17008IB

heterocyclic C_{1-4} alkyl;
 $N(R')^+_3A^-$, where R' is as
 defined above, and A^- is a counterion;
 guanidyl; heterocyclic; heterocyclic
 substituted with up to five members
 independently selected from the group
 consisting of C_{1-6} alkyl, hydroxy,
 trifluoromethyl, C_{1-4} alkoxy, halo,
 aryl, aryl C_{1-4} alkyl, amino, and
 mono- or di- C_{1-4} alkylamino; or
 heterocyclic substituted with another,
 the same or different, heterocyclic;



where

Y is as defined above;

n_a is 0 or 1;

n_b is 1 to 4;

n_c is 0 or 1;

n_d is 0 or 1;

n_e is 0 or 1, provided that n_e
 cannot be 1 when n_d is 0;

n_f is 1 to 4;

R^4 is hydrogen; or $-\underset{\underset{R^3}{|}}{CH}-R^9$, where

R^9 is hydrogen; C_{1-4} alkyl;
 hydroxy; or


41190/1252A

- 200 -

170081B



where

n is 0 or 1; and

 R^8 is as defined above; or

where

n is 0 or 1; or



where

Y is -NH- or -O-;

q is 1-5;

q' is 0-5;

 R^{10} is hydrogen; hydroxy; $N(R'')_2$,where R'' may be the same or different and is hydrogen or C_{1-4} alkyl; guanidyl; or $N^+(R'')_3A^-$, where R'' is asdefined above, and A^- is a

counterion; provided that at least

one R^{10} is not hydrogen;

R^{11} is C_{1-4} alkyl; C_{3-7} cycloalkyl; aryl; aryl substituted with up to three members independently selected from the group consisting of

 C_{1-6} alkyl, trifluoromethyl,hydroxy, C_{1-4} alkoxy, amino, mono-or di- C_{1-4} alkylamino, amino


4160o/1257A

- 202 -


17008IB

guanidyl, and guanidyl- C_{1-4} alkyl;
and
 R^{14} is carboxy, ester or amide;

5



10



where

Y is $-NH-$ or $-O-$;

k is 0-4;

15

k' is 0 or 1;


k'' is 0-4;

k''' is 0 or 1;

R' is hydrogen or C_{1-4} alkyl; and

R'' is hydrogen or C_{1-4} alkyl;

20



25

where Z is NH, $N-R^7$, O, S or CHR^7 ;

n' is 0 to 5; and

R^{7a} is hydrogen, hydroxy,

C_{1-4} -alkyl, C_{3-7} -cycloalkyl, aryl, aryl

substituted with from one to five members

30

independently selected from the group

consisting of C_{1-6} -alkyl

trifluoromethyl, hydroxy, C_{1-4} alkoxy,

amino, mono- or di- C_{1-4} alkylamino,


4160o/1257A

- 204 -

170081B


BOC-His-Pro-Phe-His-Sta-OEt

5




10

15

BOC-Phe-His-ACHPA-NH₂20 BOC-HomoPhe-His-Sta-NH₂

25








30

4160o/1257A

- 206 -

170081B




41600/1257A


- 208 -

17008IB

5




10




15

20



25







30

4160o/1257A

- 210 -





170081B



4160o/1257A

- 212 -





17008IB



4160o/1257A

- 214 -





17008IB



4160o/1257A

- 216 -





170081B



4160o/1257A

- 218 -

17008IB







30

4160o/1257A

- 220 -





170081B



4160o/1257A

- 222 -

17008IB







30

4160o/1257A

- 224 -


170081B



4160o/1257A

- 226 -





170081B



4160o/1257A

- 228 -





170081B



4160o/1257A

- 230 -

17008IB







30

4160o/1257A

- 232 -

17008IB









30

4160o/1257A

- 234 -

170081B




wher R=alkyl, aryl, -CO₂H,
-CH₂OH

41600/1257A

- 236 -







170081B



4160o/1257A

- 238 -

17008IB




41600/1257A


- 240 -

17008IB


5




10




15




20



25









30



4160o/1257A

- 242 -


17008IB




4160o/1257A

- 246 -


170081B




5




10




15



20



25



41600/1257A

- 248 -

170081B

- EtO₂C-Phe-His-ACHPA-NH-[(2S)-methyl]butyl
2(S)-hydroxy-3-phenylpropionyl-His-ACHPA-NH-
[92S)-methyl]butyl
S-benzylthioacetyl-His-Achpa-NH-[(2S)-methyl]
5 butyl
Dibenzylacety-His-ACHPA-NH-[(2S0-methyl]butyl
Bis-(naphthylmethyl)acetyl-His-ACHPA-NH-[(2S)-
methyl]butyl
Bis-(p-hydrocyphenylmethyl)acetyl-His-ACHPA-
10 NH-[(2S)-methyl]butyl
2-Phenylamino-3-phenylpropionyl-His-ACHPA-NH-
[(2S)-methyl]butyl
2-Phenyloxy-3-phenylpropionyl-His-ACHPA-NH-
[(2S)-methyl-butyl[(2S)-me
15 2-Phenylthio-3-phenylpropionyl-His-ACHPA-NH-
[(2S)-methyl]butyl
1,3-Diphenylpropyloxycarbon-His-ACHPA-NH-
[(2S)-methyl]butyl
2-(1,3-diphenyl)propyloxycarbonyl-His-ACHPA-
20 NH-[(2S)-methyl]butyl
2-Phenylthio-3-(1-naphthyl)propionyl-His-
ACHPA-NH-[(2S)-methyl]butyl
[2-benzyl-2(3,4-dihydroxy)benzyl]acetyl-His-
ACHPA-NH-[(2S)-methyl]butyl
25 [2-benzyl-2-(4-isopropoxy)benzyl]acetyl-
His-ACHPA-NH-[(2S)-methyl]butyl
BOC-Phe-His-[5-amino-6-cyclohexyl-4-hydroxy-
2-isopropyl]hexanoyl 2(S)-aminobutane
BOC-Phe-His-[5-amino-6-cyclohexyl-4-hydroxy-2-
30 isobutyl]hexanoyl 2(S)-aminobutane
BOC-Phe-His-[5-amino-2-benzyl-6-cyclohexyl-
4-hydroxy]hexanoyl 2(S)-aminobutane


1

5 5 . A pharmaceutical composition for
treating renin-associated hyperaldosteronism,
comprising a pharmaceutical carrier and a
therapeutically effective amount of a peptide
according to Claim 1.

10

6 . A peptide of the formula:

15



wherein:

20

A[°] is hydrogen, or R[°]_a-, R[°]_bCO or R[°]_bSO₂-
where R[°]_a and R[°]_b are alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, heterocyclic,
aryloxy alkyl, heterocyclic oxy alkyl, aryl
alkyl, heterocyclic alkyl, heterocyclic
oxyalkyl, and R[°]_a and R[°]_b may be

25

30

35

4160o/1257A

- 252 -

170081B

$R^{3'}$ is OH, NH_2 , $NHR_a^{3'}$, $NR_a^{3'}N_b^{3'}$, or $OR_c^{3'}$

5 where $R_a^{3'}$, $R_b^{3'}$, and $R_c^{3'}$ are separately
alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, cycloalkyl alkyl, aryl, aryl
alkyl, heterocyclic, heterocyclic alkyl,
each of which may be substituted with up to
three members selected from amino, alkyl
amino, dialkyl amino, trialkyl ammonium,
10 hydroxy, alkoxy, aryloxy, aryl alkoxy, or
halo.

$R_c^{3'}$ may also be $R_d^{3'}-CO-V'-CR_e^{3'}R_f^{3'}$
wherein $R_d^{3'}$ is alkyl or aryl; $R_e^{3'}$
and $R_f^{3'}$ are hydrogen or alkyl; V' is
15 -O- or -NH-.

$R^{4'}$ is hydrogen, alkyl, alkenyl, alkynyl, aryl,
arylalkyl, each of which may be substituted
with up to three members selected from
amino, alkyl amino, dialkyl amino, trialkyl
20 ammonium, hydroxy, alkoxy, halo or alkyl
groups. $R^{4'}$ may also be
 $R_a^{4'}-CO-V'-CR_b^{4'}R_c^{4'}$ wherein $R_a^{4'}$
is alkyl, alkenyl or alkynyl, or aryl;
 $R_b^{4'}$ and $R_c^{4'}$ are hydrogen, alkyl,
25 alkenyl, or alkynyl; V' is -O- or -NH-.

$R^{5'}$ is hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, aryl, cycloalkyl
alkyl, aryl alkyl, heterocyclic,
heterocyclic alkyl, aryloxy alkyl,
30 heterocyclic oxy alkyl, heterocyclic oxy,
each of which may be substituted with up to
three members selected from amino, alkyl
amino, dialkyl amino, trialkyl ammonium,

41600/1257A

- 254 -

170081B

8. A peptide of Claim 6 wherein $R^{1'}$ is $-\text{CH}_2\text{-cyclohexyl}$.

9. A peptide of Claim 8 wherein $R^{6'}$ is H, and n' is 1.

10. A peptide of Claim 9 wherein $R^{2'}$ is $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{-CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{-cyclohexyl}$ and $R^{4'}$ is H.

11. A peptide of Claim 9 wherein $R^{6'}$ is H, $R^{2'}$ is H, n is 0, and $R^{4'}$ is H.

12. A compound of Claim 6 selected from

- 15 [N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
2-carboxy-4-methylpentylphosphinic acid;
[N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
20 2-carboxy-3-methylbutylphosphinic acid;
[N-(N-(N-t-butoxycarbonyl-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
2-carboxy-3-methylbutylphosphinic acid;
[N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
25 2-carbomethoxy-4-methylpentylphosphinic acid;
[N-(N-(N-carbobenzoxy-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
2-carboxamido-4-methylpentylphosphinic acid;
30 [N-(N-(N-t-butoxycarbonyl-2-amino-3-(1-naphthyl)-
propionyl)histidyl)-1-amino-2-cyclohexylethyl]
2-(N-benzyl)carboxamido-3-methylbutylphosphinic
acid;

41600/1257A

- 256 -

170081B

1 Methyl [N-(N-(N-carbobenz xy-2-amino-3-(1-naphthyl)propionyl)histidyl)-1-amino-2-cyclohexylethyl]carbomethoxymethylphosphinate; and
5 Ethyl [N-(N-3-phenylpropionyl-phenylalanyl)-1-amino-2-cyclohexylethyl] 2-carbomethoxy-3-methylbutylphosphinate.

10 13. A pharmaceutical composition for treating hypertension or congestive heart failure containing a compound of Claim 6.

15 14. A pharmaceutical composition for treating hypertension containing a compound of Claim 1 or 6 and one or more antihypertensive agents selected from the group consisting essentially of:

20 Diuretics: acetazolamide; amiloride; bendroflumethiazide; benzthiazide; bumetanide; chlorothiazide; chlorthalidone; cyclothiazide; ethacrynic acid; furosemide; hydrochlorothiazide; hydroflumethiazide; indacrinone (racemic mixture, or as either the (+) or (-) enantiomer alone, or a manipulated ratio, e.g., 9:1 of said enantiomers,
25 respectively); metolazone; methyclothiazide; muzolimine; polythiazide; quinethazone; sodium ethacrylate; sodium nitroprusside; spironolactone; ticrynafen; triamterene; trichlormethiazide;

30

35

41600/1257A

- 258 -

170081B

- ((±)-3'-acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)-
acetanilide HCl) (diacetolol);
- (methyl-4-[2-hydroxy-3-[(1-methylethyl)aminopropoxy]]-
benzenepropanoate HCl) (esmolol);
- 5 (erythro-DL-1-(7-methylindan-4-yloxy)-3-isopropylamino-
butan-2-ol);
- (1-(tert.butylamino)-3-[O-(2-propynyloxy)phenoxy]-2-
propanol (pargolol);
- (1-(tert.butylamino)-3-[o-(6-hydrazino-3-pyridazinyl)-
10 phenoxy]-2-propanol diHCl) (prizidilol);
- ((-)-2-hydroxy-5-[(R)-1-hydroxy-2-[(R)-(1-methyl-3-
phenylpropyl)amino]ethyl]benzamide);
- (4-hydroxy-9-[2-hydroxy-3-(isopropylamino)-propoxy]-7-
methyl-5H-furo[3,2-g][1]-benzopyran-5-one)
- 15 (iprocrolol);
- ((-)-5-(tert.butylamino)-2-hydroxypropoxy]-3,4-dihydro-
1-(2H)-naphthalenone HCl) (levobunolol);
- (4-(2-hydroxy-3-isopropylamino-propoxy)-1,2-benziso-
thiazole HCl);
- 20 (4-[3-(tert.butylamino)-2-hydroxypropoxy]-N-methyliso-
carbostyrl HCl);
- ((±)-N-2-[4-(2-hydroxy-3-isopropyl aminopropoxy)-
phenyl]ethyl-N'-isopropylurea) (pafenolol);
- (3-[[2-(trifluoroacetamido)ethyl]amino]-1-phenoxy-
25 propan-2-ol);
- (N-(3-(o-chlorophenoxy)-2-hydroxypropyl)-N'-(4'-chloro-
2,3-dihydro-3-oxo-5-pyridazinyl)ethylenediamine);
- ((±)-N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]-
propoxy]phenyl]butanamide) (acebutolol);
- 30 ((±)-4'-[3-(tert-butylamino)-2-hydroxypropoxy]spiro-
[cyclohexane-1,2'-indan]-1'-one) (spirendolol);
- (7-[3-[[2-hydroxy-3-[(2-methylindol-4-yl)oxy]propyl]-
amino]butyl]thiophylline) (teoprolol);

41600/1257A

- 260 -

17008IB

- (1-(4-(2-(4-fluorophenyloxy)ethoxy)phenoxy)-3-iso-propylamino-2-propanol HCl);
- ((-)-p-[3-[(3,4-dimethoxyphenethyl)amino]-2-hydroxy-propoxy]-8-methylcinnamionitrile) (pacrinolol);
- 5 ((±)-2-(3'-tert.butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole HCl)
- (arotinolol);
- ((±)-1-[p-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(isopropylamino)-2-propanol) (cicloprolol);
- 10 ((±)-1-[(3-chloro-2-methylindol-4-yl)oxy]-3-[(2-phenoxyethyl)amino]-2-propanol) (indopanlol);
- ((±)-6-[[2-[[3-(p-butoxyphenoxy)-2-hydroxypropyl]-amino]ethyl]amino]-1,3-dimethyluracil)
- (pirepolol);
- 15 (4-(cyclohexylamino)-1-(1-naphtholenyloxy)-2-butanol);
- (1-phenyl-3-[2-[3-(2-cyanophenoxy)-2-hydroxypropyl]-aminoethyl]hydantoin HCl);
- (3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran) (nipradolol);

20

α and β-Adrenergic Blocking Agents:

- ((±)-1-tert-butylamino)-3-[o-[2-(3-methyl-5-isoxazolyl)vinyl]phenoxy]-2-propanol) (isoxaprolool);
- (1-isopropylamino-3-(4-(2-nitroxyethoxy)phenoxy)-2-propanol HCl);
- 25 (4-hydroxy-α-[[3-(4-methoxyphenyl)-1-methylpropyl]-aminomethyl]-3-(methylsulfinyl)-benzmethanol HCl)
- (sulfinalol);
- (5-[1-hydroxy-2-[[2-(o-methoxyphenoxy)ethyl]amino]-ethyl]-2-methylbenzenesulfonamide HCl);
- 30 (5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-salicylamide HCl) (labetalol);

4160o/1257A

- 262 -

17008IB

- (2-(N-benzyl-N-methylamino)ethylmethyl-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate HCl) (nicardipine);
- 5 (N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-N-methyl-m-dithiane-2-propylamine-1,1,3,3-tetraoxide) (tiapamil);
- (5,6-dimethoxy-2-(3-[(α -(3,4-dimethoxy)phenylethyl)-methylamino]propyl)phthalimidine) (falipamil);
- 10 (8-[(2-methylpropoxy)methyl]-N-phenyl-N-phenylmethyl-1-pyrrolidineethanamine HCl monohydrate) (bepiridil);
- ((+)-cis-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one) (diltiazem);
- 15 ((E)-1-[bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine di HCl) (flunarizine);
- (5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile (gallopamil);
- 20 (ethylmethyl(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate (felodipine);
- (isopropyl-2-methoxyethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylate) (nimodipine);
- 25 (3-ethyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylate) (nitrendipine);
- 30 Angiotensin I Converting Enzyme Inhibitors:
- 1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline (captopril);
- (1-(4-ethoxycarbonyl-2,4(R,R)-dimethylbutanoyl)-indoline-2(S)-carboxylic acid);



the technology transfer company

NERAC, Inc.
One Technology Drive
Tolland, Connecticut 06084-3900
Telephone 860-872-7000
Fax: 860-875-1749
Documents: 860-872-9331
E-Mail: nerac@nerac.com

PATENT IMAGE ORDER FOR:

Ms. Carrie Barclay
Order Number: 01450699
Patent Number: P0212903
2 of 10

005576.00

NOT AVAILABLE

Ms. Carrie Barclay
Information Assistant
Elan Pharmaceutical
800 Gateway Boulevard
South San Francisco, CA 94080

Copyright 2000 NERAC Inc. All Rights Reserved

December 13, 2000 TECH.SPEC. - World Wide Web -- Customer Acc